

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

(51) International Patent Classification⁷: A61K 45/06 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/EP01/06976

(22) International Filing Date: 20 June 2001 (20.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: SCHERING AKTIENGESELLSCHAFT [DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).


(71) Applicants and
(72) Inventors: SIEUMEISTER, Gerhard [DE/DE]; Reimerswalder Steig 26, 13503 Berlin (DE). HABEREY, Martin [DE/DE]; Steinstr. 1, 12169 Berlin (DE). THIERAUCH, Karl-Heinz [DE/DE]; Hochwildpfad 45, 14169 Berlin (DE).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/97850 A2

(54) Title: COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE RECEPTOR FUNCTION AND THEIR USE (II)

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use (II)

5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al, Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

20

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1 5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during 10 early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce 15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also 20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and 25 lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonneuve et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was 30 observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurstonen et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonneuve et al., *Science* 277, 55-60, 1997; Goede et al. Lab.

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of endothelial-periendothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al., Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led

5 to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4

15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high

20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2

25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

30 Interference with Tie2 receptor function by means of Angiopoietin-neutralizing Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 5 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl.

10 Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 15 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

20 However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon 25 combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-periendothelial cell interaction of existing mature tumor vessels and thereby 30 sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or

5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological

10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems.

15 Targeting or modulation of the biological activities of VEGF/VEGF receptor systems and of Angiopoietin/Tie receptor systems can be performed by

(a) compounds which inhibit receptor tyrosine kinase activity,

(b) compounds which inhibit ligand binding to receptors,

(c) compounds which inhibit activation of intracellular signal pathways of the

20 receptors,

(d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,

(e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents

25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,

(f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30


A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), Cancer Res. 59, 99-106; Vajkoczy et al., Proc. Am. Assoc. Cancer Res. San Francisco (2000), Abstract ID 3612; Zeneca: 5 ZD4190, ZD6474; Wedge et al. (2000), Cancer Res. 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., Proc. Am. Assoc. Cancer Res., San Francisco (2000), Abstract ID 3614; Dimitroff et al. (1999), Invest. New Drugs 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is 10 prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin 15 A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhUMAbVEGF) and by Presta et al. (1997), Cancer Res. 57, 4593- 4599. Ligand-binding receptor domains are described by Kendall & Thomas 20 (1993), Proc. Natl. Acad. Sci., U.S.A.90, 10705-10709; by Goldman et al. (1998) Proc. Natl. Acad. Sci., U.S.A.95, 8795-8800 and by Lin et al. (1997), J. Clin. Invest. 100, 2072-2078. Further, dominant negative receptors have been 25 described by Millauer et al. (1994), Nature 367, 567-579. Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), Proc. Natl. Acad. Sci., U.S.A.95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), Nat. Biotech 14, 1021-1025. Further, small molecules and peptides have been described. 30 Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59, 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci. U.S.A94, 8795-8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998), Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example molecules of general formula I

15



20

I,

in which


r has the meaning of 0 to 2,
n has the meaning of 0 to 2;

25

R₃ und R₄

a) each independently from each other have the meaning of lower alkyl,

b) together form a bridge of general partial formula II;




5

wherein the binding is via the two terminal C- atoms, and
m has the meaning of 0 to 4; or

10

c) together form a bridge of partial formula III



III,

15

wherein one or two of the ring members T₁, T₂, T₃, T₄ has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T₁ and T₄;

G

20

has the meaning of C₁ - C₆ - alkyl, C₂ - C₆ - alkylene or C₂ - C₆ - alkenylene; or C₂ - C₆ - alkylene or C₃ - C₆ - alkenylene, which are substituted with acyloxy or hydroxy; -CH₂-O-, -CH₂-S-, -CH₂-NH-, -CH₂-O-CH₂-, -CH₂-S-CH₂-, -CH₂-NH-CH₂, oxa (-O-), thia (-S-) or imino (-NH-),


A, B, D, E and T

25

independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or lower alkyl,
X has the meaning of imino, oxa or thia;
5 Y has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if 10 more than one rest Z is present (m≥2), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single or double bonds; or an N-oxide of said compound, wherein one ore more N-atoms carry an oxygene atom, or a salt thereof.
15
20 A preferred salt is the salt of an organic acid, especially a succinate.
These compounds can preferentially be used as compound I or II in the inventive pharmaceutical composition.
25 Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis, respectively, which results in a prevention of tumor growth and tumor spread, are for example
anthranyl acid derivatives of general formula IV
30

11



in which

A

has the meaning of group $=NR^2$,

5


W

has the meaning of oxygen, sulfur, two hydrogen atoms or the group $=NR^8$,

Z

has the meaning of the group $=NR^{10}$ or $=N-, -N(R^{10})-$ $(CH_2)_q$, branched or unbranched C₁₋₆-Alkyl or is the group


10



15


or A, Z and R¹ together form the group

20



	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
5	$R_a, R_b, R_c, R_d, R_e, R_f$	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/ or R_a and/ or R_b together with R_c and or R_d or R_e together with R_e and/ or R_f form a bound, or up to two of the groups R_a - R_f form a bridge with each up to 3 C-atoms with R^1 or R^2 ,
10	X	has the meaning of group =NR ⁹ or =N-,
	Y	has the meaning of group -(CH ₂) _p ,
	p	has the meaning of integer 1-4,
	R^1	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
15	R^2	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R_a - R_f together with Z or R ₁ ,
20	R^3	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of halogen, C ₁₋₆ -alkyl, C ₁₋₆ -alkoxy or hydroxy,
25	R^4, R^5, R^6 and R^7	independently from each other have the meaning of hydrogen, halogen or C ₁₋₆ -alkoxy, C ₁₋₆ -alkyl or


C_{1-6} -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R^5 and R^6 together form the group



5 R^8 , R^9 and R^{10} independently from each other have the meaning of hydrogen or C_{1-6} -alkyl, as well as their isomers and salts.


These compounds can also preferentially be used as compound I or II in the
10 inventive pharmaceutical composition.

More preferentially compounds of general formula V





15 V,
in which
 R^1 has the meaning of group





20




14



in which R⁵ is chloro, bromo or the group -OCH₃,



in which R⁷ is -CH₃ or chloro,



in which R⁸ is -CH₃, fluoro,
chloro or -CF₃


5

in which R⁴ is fluoro,
chloro, bromo, -CF₃,
-N=C, -CH₃, -OCF₃ or
-CH₂OH

in which R⁶ is
-CH₃ or chloro

R²

has the meaning of pyridyl or the group



10

and

R³ has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

These compounds have the same properties as already mentioned above under 15 compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

20

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of 25 main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions

a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

5

b) comprising one or several agents as compound I which are targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,

10

c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,

15

d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

20

e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,

25

f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,

30

g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least 10 one of

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.
Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.
- 20
- 25
- 30

The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites

5 formation in patients. It is also possible to suppress VEGF oedemas.

For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch, 10 magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as 15 preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

20 For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients 25 thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

30 The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg. The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

Combined functional interference with VEGF/VEGF receptor systems and with

5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to interference with one ligand/receptor system overlaps with the biological response to interference with a second ligand/receptor system. Alternatively, combined functional interference with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and

10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via Angiopoietin/Tie receptor systems can be performed simultaneously, or in sequential order such that the biological response to functional interference with a ligand/receptor system overlaps in time with targeting of cytotoxic agents.

15 The invention is also directed to a substance which functional interferes with both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems.

20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C, VEGF-D, PIGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2 (KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1). Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor

25 tyrosine kinases Tie1 and Tie2.

Pharmaceutical compositions of the present invention can be used for medicinal purposes. Such diseases are, for example, cancer, cancer metastasis, angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of

30 the present invention can be applied orally, parenterally, or via gene therapeutic methods.

Therefor the present invention also concerns the use of pharmaceutical compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 Example 1

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector

15 (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 1

	mode of treatment	
treatment group	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	- []	+
Group 4: A375v/sTie2	+	+

5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in
 5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of
 10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its
 15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000
 20 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of 5 the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of 10 intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing

10 recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons 15 when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducting tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducting tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is
5 superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (10 Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods (15 described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor (20 growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
10 coagulation-inducting tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducting tTF to the VEGF-A/VEGF receptor I complex and functional interference with the
20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system

and endothelium-specific targeting of a coagulation-inducing protein is superior to

5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-

10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in *E. coli* as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.

15 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducting L19 scFv-tTF (compound I, treatment group 2) grew to a 5 volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF 10 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate
10 (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducting L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the

5 Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

mock, con.	=	treatment group 1
mock+VEGF-A	=	treatment group 2
10 sTIE2-cl13	=	treatment group 3
sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of

15 VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

20 Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

25 Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in 5 Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine 10 kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
5
2. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
10
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
20
- 25 4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
30
5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
30
6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.

10

8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.

10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of

- 20 a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 25 e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 30 f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- k) delivery systems, such as antibodies, ligands, high-affinity binding 10 oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- l) delivery systems, such as antibodies, ligands, high-affinity binding 15 oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.


20

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a

14. Pharmaceutical compositions according to claims 1-11 which comprise as 25 compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as 30 compound I and/ or II at least one small molecule of genaral formula I

41



I,

in which

5


r has the meaning of 0 to 2,

n has the meaning of 0 to 2;

R₃ und R₄

- a) each independently from each other have the meaning of lower alkyl,
- b) together form a bridge of general partial formula II,

10



II,


15

wherein the binding is via the two terminal C- atoms,
and

m

- has the meaning of 0 to 4; or
- c) together form a bridge of partial formula III

20




has	wherein one or two of the ring members T ₁ , T ₂ , T ₃ , T ₄ has the meaning of nitrogen, and each others have the meaning of CH, and the binning is via the atoms T ₁ and T ₄ ;
5	
G	has the meaning of C ₁ - C ₆ - alkyl, C ₂ - C ₆ - alkylene or C ₂ - C ₆ - alkenylene; or C ₂ - C ₆ - alkylene or C ₃ - C ₆ - alkenylene, which are substituted with acyloxy or hydroxy; -CH ₂ -O-, -CH ₂ -S-, -CH ₂ -NH-, -CH ₂ -O-CH ₂ -, -CH ₂ -S-CH ₂ -, -CH ₂ -NH-CH ₂ , oxa (-O-), thia (-S-) or imino (-NH-),
10	
A, B, D, E and T	independently from each other have the meaning of N or CH, with the proviso that not more than three of these Substituents have the meaning of N,
15	
Q	has the meaning of lower alkyl, lower alkyloxy or halogene,
R ₁ and R ₂	independently from each other have the meaning of H or lower alkyl,
20	
X	has the meaning of imino, oxa or thia;
Y	has the meaning of hydrogene, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
25	
Z	has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present (m≥2), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single
30	

or double bonds; or an N-oxide of said compound,
wherein one or more N-atoms carry an oxygen atom,
or a salt thereof,

and/or a compound of general formula IV

5




in which

A has the meaning of group $=NR^2$,

10 W has the meaning of oxygen, sulfur, two hydrogen atoms
or the group $=NR^8$,


Z has the meaning of the group $=NR^{10}$ or $=N-, -N(R^{10})-$
 $(CH_2)_q-$, branched or unbranched C₁₋₆-Alkyl or is the
group

15



or A, Z and R¹ together form the group

20




	m, n and o	has the meaning of 0 – 3,
5	q	has the meaning of 1 – 6,
	R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/ or R _a and/ or R _b together with R _c and or R _d or R _e together with R _e and/ or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
10	X	has the meaning of group =NR ⁹ or =N-,
	Y	has the meaning of group -(CH ₂) _p ,
	p	has the meaning of integer 1-4,
15	R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or heteroaryl,
20	R ²	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
	R ³	has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally
25		

5 R^4, R^5, R^6 and R^7

substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,


independently from each other have the meaning of hydrogen, halogene or C₁₋₆-alkoxy, C₁₋₆-alkyl or C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R^5 and R^6 together form the group

10 R^8, R^9 and R^{10}

independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts,

and/ or a compound of general formula V

15




V,

20

in which


R^1 has the meaning of group

46




in which R^5 is chloro, bromo or the group $-OCH_3$,

5



in which R^7 is $-CH_3$ or chloro,




in which R^8 is $-CH_3$, fluoro,
chloro or $-CF_3$

5

in which R^4 is fluoro,
chloro, bromo, $-CF_3$,
 $-N=C$, $-CH_3$, $-OCF_3$ or
 $-CH_2OH$

in which R^6 is
 $-CH_3$ or chloro

R^2 has the meaning of pyridyl or the group



10

and

R^3 has the meaning of hydrogen or fluoro, as well as their
isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as

15 compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as

compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium

20 hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, Tie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium


hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

19. Pharmaceutical compositions according to claims 1-17 which comprise as
5 compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

20. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-
10 42-35.

21. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I L19 scFv-tTF conjugate and as compound II sTie2.

15 22. Use of pharmaceutical compositions according to claims 1-21, for the
production of a medicament for the treatment of tumors, cancers, psoriasis,
arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye
diseases, such as diabetic retinopathy, neovascular glaucoma, kidney
diseases, such as glomerulonephritis, diabetic nephropathie, malignant
20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation
rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver,
mesangial cell proliferative diseases, arteriosclerosis, damage of nerve
tissues, suppression of the ascites formation in patients and suppression of
VEGF oedemas.

**Fig. 1**




Fig. 2




Fig. 3






Fig. 4

**Fig. 5****Fig. 6**

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10 <120> Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use II

<130> 51867AEPM1XX00-P

<140>

15 <141>

<160> 59

20 <210> 1

<211> 1835

<212> DNA

<213> Human

25 <400> 1

ttttacagtt ttccttttct tcagagttta ttttgaattt tcattttgg ataaccaagc 60
agctctttaa gaagaatgca cagaagagtc attctggcac tttggatag tacataagat 120
tttctttttt ttttttaat ttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccacat tgggtgagca agatgagccc ataggattcc agagttataa cgtaaccgta 240
tatacaaaca gccaaaaaac cataatggtg ccacaggat ggagcaggga agggcatctc 300
taacgtgtcc tctagtctat ctgcgtaaa cagaaccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttta 420
aagcaaaaga gacatccctt aataactgta taaaatccag gcagttccat taaaggggtt 480
aagaaaacca acaacaacaa aaagcgaggg actgtctgtt gtcactgtca aaaaggcact 540
tggagttaat gggaccagga ttggaggact cttagctgat acagattca gtacgatttc 600
attaaaaggc ttggatgtta agagaggaca ctcagcggtt cctgaaggga gacgctgaga 660
tggaccgctg agaagcggaa cagatgaaca caaaggaatc aaatctttac aaccaaattt 720
catttaagcg acaacaaaaa aaggcaaaccc cccaaacgca acctaaccac agcaaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagcttcc tttgagagaa cgcatatcctt 840
40 gagacgctac gtgccaacct aagttctcaa cgacagcttc acagtaggat tattgtata 900
aaaatgactc aagcgatgca aaaagttca tctgttccca gaatccgagg gagaactgag 960
gtgatcgta gacatcgatcg acatcacgtg cggtttctta atgtccctgg tggcgatatac 1020
gcccggatctt cggaggaca tctggacacc actttcagcc acctcccttc agggggcaca 1080
tccggccaaag tcatcctta ttccgagtaa taactttat tcccttctaa catttacacg 1140
45 gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgttcc 1200
ctccacgaac gggtaacgcgc ttccatgaga aaggatattt ggcaattttt tattccacag 1260
tcaggtgggt ctgcgatagc tcatttaatg ttaaacgcca tcaggggcct ctcccccgt 1320
ttctggcagg ggctttctt gtcttcctt tggcgagctc gtggggcagat cttctctgtt 1380
50 gggggctggc tgctggctcc gagggggcat cccgagatccg tctggctgcc tcctcctgca 1440
ggctgggcag ctggccacca cttctccgac tcgacccttc caacaagcat cgcatggcac 1500
tgtcctcgaa ggtacagacc gtggtcccac attcgctacc actctgttcc acgtcatcca 1560
ggtacacgag ctgcgtgttag gccgtgtgt ctggggctcg aggctcttc tgctgggtgt 1620
cttggacggg cgggttagttc tgctgcagag acaaagcatc tcccttccc ttccgggtcg 1680
attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740
55 cagcttttg gagaatcaat gtatgaatgt ctaacctgac cggtggaccc gccatccaag 1800
gagacgaacc acgccccgggg gtgcggaaagc ggcct

60 <210> 2

<211> 581

<212> DNA

<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct cttaaagaccc ctggggcctg tgctacccag 60
acactaaca cagtcttat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
tcaacttact tcctgtggcc cattagggaa gtggtgaccc cgggagctat ttgcctgtt 180
agtgcacaca cctggaaaca tactgctctc atttttcat ccacatcagt gagaatgag 240
tggcccgta gcaagatata actatgcaat catgcaacaa agctgcctaa taacattca 300
tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
10 agttatagtt catabacagt tgatttccat ttataaaggc agaaagtccct tgtttctct 420
aaatgtcaag ctttgactga aaactcccgt tttccagtc actggagtgt gtgcgtatga 480
aagaaaatct ttagcaatta gatgggagag aaggaaata gtacttgaaa tgtaggccct 540
caccccccac tgacatcctc catgagcctc ctgatgttagt g

15 <210> 3
<211> 516
<212> DNA
<213> Human

20 <400> 3

tagagatgtt ggttgatgac ccccggtac tggagcagat gaatgaagag tctctggaag 60
tcagccaga catgtgcac tacatcacag aggacatgtt catgtcgccg aacctgaatg 120
gacactctgg gttgattgtg aagaaaattt ggtcttccac ctcgagctct tcagaaacag 180
25 ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240
agacctccac tgatcgacac agcttgagcc tcgatgacat cagacttac cagaaagact 300
tcctgcgcac tgcaggctcg tgcaggaca ctgcctcagag ttacaccttt ggtatgtggcc 360
atgaacttggaa tgaggaaggc ctctatttgc acagttgctt ggccagcag tgcataaca 420
tccaagatgc ttttccagtc aaaagaacca gcaaatactt ttctctggat ctactcatg 480
30 atgaagttcc agagttgtt gtgtaaagtc cgtctg

<210> 4
<211> 1099
<212> DNA
<213> Human

<400> 4

40 cccacaacac agggccctg aaacacgcca gcctctcctc tgggtcagc ttggcccagt 60
cctgctcaact ggatcacacgc ccattttagg tggggatgg tggggatcag ggcccctggc 120
ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggtg ccctgggtcg 180
gggtgtcgctc ttggccttgc cgtccctca tccccggct gaggcagcga cacagcaggt 240
gcaccaactc cagcaggta agcaccagg agatgagttc aaccaccaac atgaagatga 300
tgaagatggt cttctccgtg gggcgagaga caaaggagtc caccggatgg gggcagggtg 360
45 ctcgctggca cacaacacgc ggctccatgg tccagccgtc caggcgccac tggccataga 420
ggaaggcctgc ctctagcaca ctcttgcaga gcacactggc gacatagggtg cccatcagt 480
ctcccgccgat ggcaggcga ccatcttctg ccaccggat ctggccatc tgacgctcta 540
cgcccgccag cgcccgctcc acctgtgggt cttggccgg cagtgcggc agctccccct 600
ccttctggcg cagccgtct tctcgccag acaggtaat gacatggccc agtagacca 660
50 gggtgtgggtgt gctgacgaaag aggaactgca gcacccagta gggatgtgg gagatgggaa 720
aggcctggtc atagcagacg ttgggtgcagc ctggctggc cgtgttacac tcgaaatctg 780
actgctcgtc accccacact gactgcgg ccaggccag gatgaggatg cgaaagatga 840
agagcaccgt cagccagatc ttacccacca cggtcgagtg ctccctggacc tggccagca 900
55 acttctccac gaagccccag tcacccatgg ctcccgccg tccgtcggca aggagacaga 960
gcacgtcagt gtgtcagcat ggcaccccttc tcgttcggcc agcaacaagc ctgcaggag 1020
gtctgccacg cccgttctac cgcctgcctg ccggccggcc cagggtggagg tggggacgat 1080
ggccggagtg acgcccccg

60 <210> 5
<211> 1015
<212> DNA
<213> Human

65 <400> 5

gaggataggg agcctgggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

<212> DNA
<213> Human

5 <400> 7

5 gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataattctg taaagaaatg aagaccttgc 120
tattctaaaa tcagatcctt acagatccag atttcaggaa acaaatacat agggactaa 180
10 ctttccttgt tcagattagt tttctcctt tgcacccagc tatataatat gaggaagtat 240
tgactttta aaagtgtttt agtttccat ttctttgata tgaaaagtaa tatttcggga 300
gaaccctgag ctattaataa tctatgtggc tagtgcgtat atattggctc gaatttggc 360
tcctttgtg gtgtccagtg ggttaacatc

15 <210> 8
<211> 157
<212> DNA
<213> Human

20 <400> 8

20 tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgttag 60
gaagcagggaa gcaagccac tcaaacgtga aatttggcat gaggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagttga tattttg

25 <210> 9
<211> 561
<212> DNA
<213> Human

30 <400> 9

30 aatagtcaaa acataaacaa aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttggc gctgacatac aggctcagcc agcagagaaa gaattctgaa ttccccttgc 120
35 tgaactgaac tattctgtta catatgttg acaaattctgt gtgttatttc ttttctacct 180
accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tcatgtacat 240
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgggtcatt caagatttt 300
tgatgttga aggaaaagtg aatatgacct ttaaaaattt tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420
40 ttaaacctat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgatc 480
ttttctttaa aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgccccat ttcttaggaaa a

45 <210> 10
<211> 1508
<212> DNA
<213> Human

<400> 10

50 50 cacaaacacg agagactcca cggctctgcct gagcaccgccc agcctcctag gctccagcac 60
tcgcagggtcc attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgccga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctccctccgg gcctgttgc gatggcataa tccgggtgca acccaaatct 240
55 gagctcaage caggtgagct taagccactg agcaaggaag atttgggcct gcacgcctac 300
aggtgtgagg actgtggcaa gtgcaaattgt aaggagtgc cttacccaaag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcct tgctcgccccc agaacgtgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgtga tgaggacaac 480
tgtgctgaca acccatgttc ttgcagccag tctcaactgtt gtacacgatg gtcagccatg 540
60 ggtgtcatgt ccctctttt gccttgcataa tggtgttacc ttccagccaa gggttgcctt 600
aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccctg taaaaactca 660
aacacagttt gctgcaaagt tcccactgtc cccccctagga actttgaaaa accaacatag 720
catcattaat caggaatatt acagtaatga ggatttttc tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataatctgg cactgttaat agaaaagttgg gatagtcttt 840
65 gctgtttgcg gtgaaatgct ttttgcctat gtgccgttt aactgatatg cttgttagaa 900
ctcagctaatttggagacttgg cagaacttgg tgacccatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaaag tttttgtttt tgaatagtagc ttgcaaaaact 1020

tgtaaatttag cagatgactt tttccattg tttctccag agagaatgtg ctatatttt 1080
gtatatacaa taatattgc aactgtaaa aacaagtggt gccatactac atggcacaga 1140
cacaaaatat tatactaata tgggtacat tcgagaagaat gtgaatcaat cagtagtgg 1200
ttagattgtt tttgcctt cagaaagctt ttattgtaa actctgattt cccttggac 1260
5 ttcatgtata ttgtacagtt acagtaaaat tcaaccttta tttctaatt tttcaacat 1320
attgttagt gtaaagaata tttatgtaa gttttattat tttataaaaaa agaatattt 1380
tttaaagagg catcttacaa atttgcctt tttatgagg atgtgatgt tgctgcaa 1440
gaggggttac agatgcataat gtccaaatata aaatagaaaa tatattaacg tttgaaatta 1500
aaaaaaaaa
10 <210> 11
<211> 389
<212> DNA
<213> Human
15 <400> 11
ggcaggtga tcagggcaca catttccgt ccattgagac agtagcatc ccggcaccca 60
20 tcgtgccagc tctcctcatt tttatgtga tgaccatcca cggtagaca agtgcggc 120
aggatgggtg gcccagctga agcacaggcc gctctgcact tgtagataag acagccgtga 180
ctgtctgtct ggaaacccaa gggcagatc ttactgcatt agagctctgg acatttctt 240
cagcagaca tgcacagcc gtcattttt ttcagcaatc caagtggaca atacttgtca 300
cagattatgg gtctgcactt ctgggcctt gggcggact cacagatctc acagtttg 360
25 acctcgcccg cgaccacgct gggtaaccga
<210> 12
<211> 981
<212> DNA
<213> Human
30 <400> 12
ttttttttt ttggattgca aaaattttt aaaattggag acactgtttt aatcttctt 60
tgccatgaga ctccatcagg cagtctacaa agaccactgg gaggctgagg atcacttg 120
35 cccagaagtt tgaggctgtt gtaagcttca aaggccactg cactctagct tgggtggc 180
aagaccctt caagcgttca gctgcatttgc tgcttgggtt ggtcattaaa aacccttagt 240
taggataaca acatattttt cagggcaaaa tacaaatgtt tgatgctt tagtagata 300
acctcagaat caaaatggaa cggtttaca gtgatattat tatatttcat ttggcagaat 360
cattacatca ttggtttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420
40 taggataaca ggtctgcctt tttgaagatg aaaaataata cccattttaaa atttgcctt 480
ctcaatttcc ttctcagtca cattttact tttaaacagc taatcactcc catctacaga 540
ttaaggtgtt tatgcacca aaacctttt ccaccttaaa aatttccctt aaagttttaaa 600
ctaattgcctt cattttttca atcatgtt ctgacttcc ttgttcttta aaacttgctc 660
45 cacacagtgt agtcaagccg actctccata cccaaagcaag tcattccatgg ataaaaaacgt 720
taccaggagc agaaccattt agctggtcca ggcaagttgg actccaccat ttcaacttcc 780
agctttctgt ctaatgcctt tttttttttt gcttggatgtt ggcttgcctt ttaggacttc 840
agtagctatt ctcattttttt cttggggaca caactgttcca taaggtgttca tccagagcca 900
cactgcattt gcaccacgca ccataccatca caggagtcga ctcccacgag ccgcctgtat 960
ataagagttc ttttgcattt g
50 <210> 13
<211> 401
<212> DNA
<213> Human
55 <400> 13
ataactacag ctccagcaga caactaaaga gactgcattt aggtgatcc tctggctata 60
aagagagccc ggccgcagag catgtgactt ctgggaccc tcggataggc aacactgc 120
60 tctctccccc agagcgaccc cccggcagg tcggggccca aggaatgacc cagcaactgc 180
tccctaccca gcacacttc tttactgcca cctgcaattt tgctgtgaag atgactgggt 240
gtggtcatca cgattcagag aaatcaagat ctatgaccat tttaggcaaa gagagaaact 300
tggagaattt ctgaggacta ctgaaccttgc ttttgcattt tttttttttt tttttttttt 360
acttcagcat atttttttttt cattttttttt aagctgatattt t
65 <210> 14

<211> 1002
<212> DNA
<213> Human

5 <400> 14

10	gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
	acagttgtgg agaacaggtt gagtagagca acaacaacaa aagcttatgc agtcaccc 120
	tttggaaaatg ttaaataacaa gtcctattct ctttgcaggat ctgggtttag ctagaggtag 180
	ccaattactt ctcttaaggt ccatggcatt cgccaggatt ctataaaagc caagtttaact 240
	gaagtaaata tctggggccc atcgaccccc cactaagtac tttgtcacca tgggttatct 300
	taaaagtcat ttttcactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
	ttactccaaa cccagttaa ttccccactt ttttaagtag gcttagctt gagtgatttt 420
	tggctataac cgaaatgtaa atccaccc 480
15	aaacaacaaa gtttgacaag actgaaatgt
	tactgaaaac aatggtgcca tatgctccaa 540
	tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct 600
	attaatacag ctcaaatgga gtagtaacca agctttctg cccaggaagt aacaaacatc 660
	actacgaaca tgagagtaca agaggaaact ttcataatgc atttttcat tcatacattc 720
	attcaataaa cattagccaa gctaatgtcc caagccactg tgccaggtat taacaatata 780
20	acaacaataa aagacacagt ctttcctctc aagggtttca gtctagtagg gaagatgatt 840
	attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaattcct 900
	gcctatgttc tcagatattc tggttaggtc aggagtggga acccaaaaatc aattctttta 960
	acaaaacacta aagggtgattc taacacaggc ggtgtgagga cc

25 <210> 15
<211> 280
<212> DNA
<213> Human

30 <400> 15

35 cgaggtggc caccgtgtc tggctgaga ttttaatg aggattacat ttcctattt 60
ataatattcc tattctaattc tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
aacattatt agaaacaaac tgcctaatac cttataagac taaaaaaaaatc accaagatga 180
aactgttata tgactctcaa tatttaaaca ttaaaaaaaaa tgtagtggtt tgttaagcac 240
caatcttaac tatttcaccc gcccgggcgg ccgctcgagg

40 <210> 16
<211> 2041
<212> DNA
<213> Human

<400> 16

45	ccccccgcag aactcccccc tggaatagga ttttaaaac cttgacaat tagaaatcct 60 atagaggtta gcattttta gtaaaaaata tggtgcccc tacagggatc atgcaacttc 120 ctaaaaacca attcagcaca tatgtataaa gaacccttt taaaaacatt tgtacttgaa 180 atacagacac agtgatgctg aagacactaa aaaaaactg aaaagtacta taccttgata 240 aattttgtta ttgccttcct tagagacttt ataatctca gttgatttc aaggacttga 300
50	atthaataat gggtaatta cacaagacgt aaaggattt taaaaacaa gtatTTTT 360 ttacctctag catcaattct tttataaaaga atgctaaata aattacattt ttgttcagt 420 aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattaggac 480 caggtacata tttcttctg aacattttg gtcaagcatg tctaaccata aaagcaaatg 540 gaattttaag agtagattt ttttccatg atgcatttg ttaataaaatg tgtcaagaaa 600
55	ataaaaaacaa gcactgagtg tttctcttg aagtataagg gtctaataatg aaataaaaga 660 tagatatttg ttatagtctg acatttaac agtcatagta ttagacgtt cgtgaccagt 720 gcattttgga ctctctcagg atcaaaaatac gagtctgcc aactgtattaa atcctcc 780 accccttcca ccagttggtc cacagttcc tgggggtcg ttgtcatcaa atccattggg 840 ccgaaatgaa catgaagcag atgcagctt gaggcccgg gctcgagcat tcaactttg 900
60	ttcctgtaaa tatagttat tgtctttgt tatacgatcc ataagttctt tctgttagagg 960 tgggtctcca ttatccaga gtccactgg tgggttatta ccacttaaac cattagtact 1020 atgctgttt ttataaaaaa gcacataagc tgtgtccctt ggaaacctgc tcgtatTTT 1080 ctggactgac tgaatgaag taaatgtcac tctactgtca taaaataaaa acccattctt 1140 ttgacatttc cttatTTCC aaatcctgtt caaaaactgc actgggacta tctctcccta 1200 gtaaatgact ctgggaggat gctaattgcca gagcctcaga ctgggtgtac atctgatatg 1260
65	aaqaqtctgt acttgtata tttctggcat aagaatagta atgcccactt tcagaggata 1320

taccagagt aaccacaacg gaacttaata gataggcac caatttgc 1380
 catcagtccc tgaaggctt aatttttag caaggtctc actaagatca gtgaagtcaa 1440
 catctacaga ccaacttct gacaatgaag agaaaagaagt aattttctc actggcaact 1500
 ccaaaaccag tggccagtga tacattgtct aaaatttcc ttctcacatg atacttctga 1560
 5 tcatatgaaa atctcaggag agtaagaata aggtattcag gttcctccgt gatttgcata 1620
 gtttctcag cattttgcag agaggcacag ttttcacaat aatattgggtt atcaccagta 1680
 agaatctctg gagcccaaaa aataatttag taagtcagtt actgaaggtg tggtttcacc 1740
 tcccggttgc tgaggtacat ctttattaac aagaatctt gtagattcgt tagggacaga 1800
 agtgtttca gaacagtaaa actcattagg aggactgcct atggtttt cattcacaag 1860
 10 tgagtacag atgaaggcag ctgttgtgg attataaact actggctctt ctgaaggacc 1920
 gggtacagac gcttcattt gaccaccatc ttgtatactg ggtgatgatg ctggatctt 1980
 gacagacatg tttccaaag aagaggaagc acaaaacgca agcggaaagat ctgtaaaggc 2040
 t
 15 <210> 17
 <211> 235
 <212> DNA
 <213> Human
 20 <400> 17
 cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagaccctc 60
 acctctacaa ataaaaaatt aaaaaattag ccaggtgtgg cagcgaacaa ctgttagtctc 120
 25 agataactcag gagactgagc tggaaaggat cacttgagcc caagaagttc aaggttacag 180
 tggccacga tcatgtcatt acactccagc ttgggtgaca aaatgagact gtcta
 <210> 18
 <211> 2732
 <212> DNA
 30 <213> Human
 <400> 18
 gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60
 35 tcatgttcat aactacttta tatggagctt cattggacct gttaccttca ttattctgtc 120
 aaatattatc ttcttggta tcacattgtg caaaatggtg aagcattcaa acactttgaa 180
 accagattct agcaggttgg aaaacattaa gtcttgggtg ctggcgctt tcgctcttc 240
 gtgtcttctt ggcctcacct ggtcctttgg gttgctttt attaatgagg agactattgt 300
 gatggcatat ctcttacta tatttaatgc tttccagggta gtttcattt tcatcttca 360
 40 ctgtgcttc caaaagaaaag tacgaaaaaga atatggcaag tgcttcagac actcatactg 420
 ctgtggaggc ctcccaactg agagtccccca cagttcaatg aaggcatcaa ccaccagaac 480
 cagtgcgc tattcctctg gcacacagag tcgtataaga agaatgtgga atgatactgt 540
 gaaaaacaa tcagaatctt ctttatctc aggtgacatc aatagcactt caacacttaa 600
 tcaaggtggc ataaatctt atatattt acaggactga catcacatgg tctgagagcc 660
 45 catcttcaag atttataatca ttttagaggac attcaactgaa caatgccagg gatacaagt 720
 ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgctg cacaagggtg 780
 actataatga cagcgtgcaa gttgtggact gtggactaag tctgaatgt actgctttt 840
 agaaaaatgtt catttcagaa ttagtgcaca acaacttacg gggcagcagc aagactcaca 900
 acctcgagct cacgctacca gtcaaaccctg tgattggagg tagcagcagt gaagatgatg 960
 50 ctattgtggc agatgttca tcttaatgc acagcgacaa cccagggtg gagctccatc 1020
 acaaagaact cgaggcacca ttatttctc agcggactca ctcccttctg taccacccccc 1080
 agaagaaaagt gaagtcccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140
 aagatcacct acagtccccca aacagagact ctctttatac aagcatgccc aatcttagag 1200
 actctccctt tccggagagc agccctgaca tggaaagaaga cctctctccc tccaggagga 1260
 55 gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320
 agatgtgcta ccagatcagc aggggcaata gtgttggta tataatcccc attaacaaag 1380
 aagggtgtat tccagaagga gatgttagag aaggacaaat gcagctggtt acaagtcttt 1440
 aatcatacag ctaaggaatt ccaaggccca catgcgagta ttaataaata aagacaccat 1500
 tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgggttctc 1560
 60 tgggtgtaaaa aagatgactg aaccttgcag ttctgtgaat ttttataaaa catacaaaaa 1620
 ctttgttat acacagagta tactaaagtg aattattgt tacaagaaaa agagatgcac 1680
 gccaggtatt ttaagattct gctgctgtt agagaaattt tggaaacaagc aaaacaaaaac 1740
 tttccagcca ttttactgca gcagtcgtg aactaaattt tggaaatatgg ctgcaccatt 1800
 tttgttaggcc tgcattgtat tatatacaag acgttagctt taaaatcctg tggacaaat 1860
 65 ttactgtacc ttactattcc tgacaagact tggaaaagca ggagagat tctgcattc 1920
 tttgcagttc actgcaaatc ttttacattt aggcaaaatg tggacaaat cttaaccact 1980

agcaatcaag ccacaggcct tatttcataat gttcctcaa ctgtacaatg aactattctc 2040
 atgaaaaatg gctaaagaaa ttatattttg ttctattgct agggtaaaat aaatacattt 2100
 gtgtccaaact gaaatataat tgcattaaa ataattttaa agagtgaaga aaatattgtg 2160
 aaaagctttt gttgcacat gttatgaaat gtttttctt acacttgc atggttaagtt 2220
 5 ctactcattt tcacttcctt tccactgtat acagtgttct gctttgacaa agtttgttctt 2280
 tattacttac atttaaattt cttattgcca aaagaacgtg ttttatgggg agaaacaaac 2340
 tcttgaagc cagttatgtc atgccttgc caaaagtgtat gaaatctaga aaagattgtg 2400
 tgtcacccct gtttatttctt gaacagaggg caaagaggc actgggcact tctcacaaac 2460
 tttctagtga acaaaagggtg cctattctt ttaaaaaaaaaa taaaataaaa cataaatattt 2520
 10 actcttccat attccttctg cctatattt gtaattaattt tattttatga taaagttcta 2580
 atgaaatgtt aattgttca gcaaaattct gctttttt catcccttgc tgtaaacctg 2640
 ttaataatgtt gcccattact aatatccagt gtaaagttt acacggttt acagtaata 2700
 aatgtgaatt tttcaagtt aaaaaaaaaa aa

 15 <210> 19
 <211> 276
 <212> DNA
 <213> Human

 20 <400> 19

 ctccctaaat gattttaaaa taaattggat aaacatatga tataaagtgg gtactttaga 60
 aaccgcctt gcatatttt tatgtacaaa tctttgtata caattccgat gttccttata 120
 25 tattccctat atagcaaacc aaaaccagga cctcccaact gcatgcctca agtccctgtg 180
 gagcactctg gcaactggat gcccctactt gtttctgac aaaatagctg gaaaggagga 240
 gggaccaattt aaataccctg gccgcgacca cgctgg

 <210> 20
 <211> 2361
 30 <212> DNA
 <213> Human

 <400> 20

 35 attgtaccag cttgtatgaa cgtggccct gttcgctt tgaggccat aagtcattt 60
 cccactggtt tagaggctac ttatcattt tctccgtt ccggaaagggt tctcccaagt 120
 cagagtttac cagcaggat tcacagagct ccgacaagca gattctaaac atctatgacc 180
 tgtcaacaa gttcatagcc tatagcaccg tctttgagga ttagtggat gtgttgcgtg 240
 40 agtggggctc cctgtacgtg ctgacgcggg atggcggtt ccacgcactg caggagaagg 300
 acacacagac caaaactggag atgcttttta agaagaacctt attttagatg gcgatttacc 360
 ttgccaagag ccagcatctg gacagtatg ggctggccca gattttcatg cgtatggag 420
 accatctcta cagcaaggcc aaccacatg gggctgttca gcaatatac cgaaccattt 480
 gaaagtttga gccatcttac gtatccgca agtttcttggat tgcccagcgc attcacaacc 540
 tgactgccta cctgcagacc ctgcaccgc aatcccttgc caatgcgcac cataccaccc 600
 45 tgctctcaa ctgtatacc aagtcagg acagtcgaa gctggaggat ttcatcaaga 660
 aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaaggatc ctccggcagg 720
 ctggctacta ctccccatgccc ctgtatctgg cggagaacca tgcacatcat gagtggat 780
 tgaagatcca gctagaagac attaagaattt atcaggaagc cttcgatatac atcggcaagc 840
 tgccttttga gcaggcagag agcaacatga agcgtacgg caagatccctc atgcaccaca 900
 50 taccagagca gacaacttgc ttgttgcagg gactttgtac tgattatcgg cccagcctcg 960
 aaggccgcag cgataggag gcccaggct gcaggccaa ctctgaggat ttcatcccc 1020
 tctttgccaa taaccgcga gagtgcggat ctttgcgttgc gacatgatg gaagtgcagc 1080
 cagactcacc ccaggggatc tacgacacac ttcttgcgttgc gcgactgcag aactggccc 1140
 acgagaagga tccacaggatc aaagagaagg ttcacgcaga ggcatttcc ctgctgaaga 1200
 55 gtggtcgtt ctgcgtacgg tttgacaagg ccctggcctt gtgcaggatg caccacttcc 1260
 aggtgggtt ctttacctt tatgagcagg ggaagctgtt ccagcagatc atgcactacc 1320
 acatgcagca cgagcagtac cggcaggatc tcagcgtgtg tgacgcgcattt gggaggcagg 1380
 accccttcctt gtggggcag gcccctcgtt acttcgatgc caaggaggat gactgcagg 1440
 agtatgttgc agtgccttca aagcatatgc agaacaagaa cctcatgcca cctcttctt 1500
 60 tgggtcagac cttggccac aactccacatg ccacacttgc cgtcatcagg gactacctgg 1560
 tccaaaaactt acagaaaacatg agccaggatc ttgcacaggatg tgacgcgcgtt 1620
 accgagagga gaccacccgt atccgcagg agatccaaat gctcaaggcc agtcctaaga 1680
 ttttccaaaa gaccaagtgc agcatctgtt acagtcgttgc gtagttgcctt tcagtcact 1740
 tcctgtgtgg ccacttccttcc caccacact gctttgagat ttactcggaa agtgcgttgc 1800
 65 actgccccac ctgcctccctt gaaaaccggatc aggtcatgga tatgatccgg gcccaggaaac 1860
 agaaacgaga ttcctatgtt caattccatgc atcagcttgc gtccttgcattt 1920

ctgtgattgc tgactacttt ggcagaggtg tttcaacaa attgactctg ctgaccgacc 1980
 ctcccacagc cagactgacc tccagcctgg aggctggct gcaacgcac ctactcatgc 2040
 actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100
 5 agaacagaca caatgggacc tgggcggcg ttacacagaa ggctggctga catgcccagg 2160
 gctccactct catctaatgt cacagccctc acaagactaa agcggaaactt tttctttcc 2220
 ctggccttcc ttaattttaa gtcaagcttgc acaatccctt ccttttaac taggcagggtg 2280
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaaacc tcctgaagtt 2340
 ttggaaaaaa aagctggttt c

10 <210> 21
 <211> 179
 <212> DNA
 <213> Human

15 <400> 21
 aggtgttaga tgctctgaa aaagaaaactg catctaagct gtcaagaaatg gattcttta 60
 acaatcaact aaaggaactg agagaaaacct acaacacaca gcagttagcc cttgaacagc 120
 20 tttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc
 <210> 22
 <211> 905
 <212> DNA
 <213> Human

25 <400> 22
 tttttttttt ttctttaacc gtgtggctt tatttcagtg ccagtgttac agatacaaca 60
 30 caaatgttcc agtttagaagg aattcaaacg gaatgccaag gtccaagcca ggctcaagaa 120
 ataaaaaggg aggtttggag taatagataa gatgactcca atactcaact ttcctaaggg 180
 caaaggtaact ttgtatcacag agtctgatct ttgaaactgg tgaactcctc ttccacccat 240
 taccatagtt caaacaggca agttatggc tttaggacac tttaaaatgg gtggtggaa 300
 tagggtcatt aataactatg aatatactt tttagaaggtg accattttgc actttaaagg 360
 35 gaatcaattt tgaaaatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420
 gggagctgga agagccttgg aagtttctat tacaataga gcaccatatac cttcatgcca 480
 aatctcaaca aaagctctt ttaactccat ctgtccagtg ttacaaata aactcgcaag 540
 gtctgaccag ttcttggtaa caaacataca tttgtgtgtc ttgtgtata cagcaatgca 600
 cagaaaaggc taccaggagc ctaatgcctc tttcaaaatcg tggggaaacc agtagaaaaa 660
 40 ggcagggctc ctaatgtcc attattacat ttccattccg aatgccagat gttaaaatgt 720
 cctgaagatg gtaacccagc tagtgaggaa taaatacccc accttgccca gtccacagag 780
 aaacaacagt agaaagaagg ggcaacttgc tgctgcagag acaaagttag tttttttcg 840
 ccatggattt cagtcctctc ctccagacca gctgcttatt tcctcagggg cccaggaaat 900
 gttga

45 <210> 23
 <211> 2134
 <212> DNA
 <213> Human

50 <400> 23
 ggtctttct ttcctttttt ttttccaaa agtgttcttt tatttcagtg aacatataatt 60
 gtataaaatac tctattttat atgcacttcc acaaaaagcga tataatttaa aagttttttt 120
 cattagaaat aaatgtataa aaataaaatg tttattatag gcatttatta ctaactatag 180
 55 tccttcttgg aaggaacacc caaaccata cttataaagt acatgttaatt tataatgaa 240
 tattttacta tatacatatg gaaaaatca tatttcacca gaagagctga acagacattc 300
 accaggatac gactgttggc ccagctgctg gagatggacc tgctaccctt cagcagccctc 360
 cccaccacaa gacaagtgtt ctaatgtcc ccaaaacctgt gggaccctgt tctacacacc 420
 tcattttgt tccggcgat tcccttcattt gtgtgattgt actgattttc atgagacaca 480
 60 agttacttct ttaatccatattccaaag cagggttaca ttgttagggaaa gaaaggaaat 540
 tggaggtact aagctcattt gttctcttcc agcttttacc agcatctaattt gcttcactgc 600
 ttttttcca ttgttagactt taatgcactt gaataaaatac atggagttgt tttttctca 660
 aaatgaatta cacaataaa gactgagatg gtccaaaaaaa gaaaagagga agccatttgc 720
 65 gttatttcac gttgctgagc ctttctctca ttgtgaacaa tctgaagttt taattctcg 780
 tagaaataat gtataaaacat tctctgaaac catagcagcc ataaacagtg ctggtaaag 840
 atcctatttg tactccttcc tccccccattt gtttagtggg taaagtaaaa caggctttag 900

taaaatctca ctttctcct actttcatt tcccaacccc catgatacta agtatttgat 960
 aagtaccagg aaacagggt tgtaatagtt ctaactttt ttgacaattg ctttgggtt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgccgg ggcttatta 1080
 5 tgctatatca ctgctcagag gttataatc ctcactaact atcctatcaa atttgcact 1140
 ggcagttac tctgatgatt caactcctt tctatctacc cccataatcc caccttactg 1200
 atacaccta ctggttactg gcaagatacg ctggatccct ccagccttct tgcttccct 1260
 gcaccagccc ttcctcaactt tgccttgcct tcaaagctaa caccactaa accacttaac 1320
 tgcattctgc cattgtgcaa aagtctatga aatgttttagg tttctttaaa ggatcacagc 1380
 tctcatgaga taacacccct ccatcatggg acagacactt caagcttctt ttttgcatac 1440
 10 cttcccaaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500
 ggtctgcaca aggtctggtg ctggctgct tcacttcctt tgcacactcg gaagcaggct 1560
 gtccattaaat gtctcgcat tctaccagtc ttctctgcca accaattca catgacttag 1620
 aacattcgcc ccactttca atgacccatg ctggggaaat gggatagca ttgaaagatt 1680
 ctttcttctt ctttacgaag taggtgtatt taatttttagg tcgaaggca ttgcccacag 1740
 15 taagaacctg gatggtcaag ggcttttga gagggctaaa gctgcgaatt ctttccaatg 1800
 ccgcagagga gccgctgtac ctcaagacaa cacccttta cataatgtct tgctctaagg 1860
 tggacaaaatgt tagtccacca ttaagaatat atgtgccatc agcagcttg atggcaagaa 1920
 agctgccatt gttcctggat cccctctgtt tccgctgtt cacttcgatg ttggggctc 1980
 20 cagttgaat tgcataatc tcatgatatac caggtttgc actagtaact gatcctgata 2040
 ttttttaca agtagatcca tttccccgc aacaccaca ttatcaaac ttcttttgg 2100
 agtctatgat gcgatcacaa ccagcttta caca

<210> 24
 <211> 1626
 25 <212> DNA
 <213> Human

 <400> 24

 30 ggacaatttc tagaatctat agtagtatca ggatataattt tgctttaaaa tatattttgg 60
 ttattttgaa tacagacatt ggctccaaat ttcatctt gcacaatagt atgactttc 120
 actagaactt ctcaacattt gggactttg caaatatgag catcatatgt gttaggctg 180
 tatcattaa tgctatgaga tacattttt tctccctatg ccaaacaggt gaacaaacgt 240
 agtttttt tactgatact aaatgttggc tacctgtat tttatagtat gcacatgtca 300
 35 gaaaaaggca agacaaatgg cctcttgc tgaatactt ggcaaaactt ttgggtctc 360
 atttctgac agacaggatt tgactcaata tttgttagagc ttgcgttagaa tggattacat 420
 ggtagtatg cactggtaga aatggttttt agttatttgc tcagaattca tctcaggatg 480
 aatctttat gtcttttat tgtaagcata tctgaatttta cttataaaat atggttttag 540
 aaagctttgt ctaaaaattt ggccttaggaa tggtaacttcc atttcaggat gccaagggg 600
 40 agaaaaataa tatgtgtgtt gttatgttta tgtaacata ttattaggtt ctatctatga 660
 atgtattttaa atattttca tattctgtga caagcatttta taatttgc当地 caagtggagt 720
 ccatttagcc cagtggaaa gtcttggaaac tcaggatcc ctgaaggat atgctggcag 780
 ccatctttt gatctgtct taaactgtaa ttatagacc agctaaatcc ctaacttgaa 840
 tctggaatgc attagttatg ctttgatcca ttcccaat ttcaggggca tcgtgggtt 900
 45 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
 atcctaacta actggcctc aactcaagca gagtttcttcc actctggcact tgcatac 1020
 aaacttagta gaggggattt tgcattttt atacaattt aatacaatgt ttacattga 1080
 taaaattctt aaagagcaaa actgcattttt atttctgcat ccacattcca atcatattag 1140
 aactaagata ttatctatg aagatataaa tggtgcaagag agactttcat ctgtggattt 1200
 50 cgttggctt tagggccctt agcactgtatg cctgcacaag catgtatgtat gtggaaataaa 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctggatc tgcaatcaca 1320
 atgcagatg gtgtttatgg gctatttgc taagtaatgt gtaagatgt atgaagtaag 1380
 tgcattttttt ttcattttt gggaaacttctt gatgcattgtt cttttgtatg gaataaaattt 1440
 55 tggtgcaata tgcattgttcc caactttgc tttttttttt atttataatgt 1500
 attatacctg tcacgcttctt agttgcattca accattttt aaccattttt gtacatattt 1560
 tactgaaaa tattttaaat gggaaattttaa ataaacattt gatgtttac ataataaaaa 1620
 aaaaaaa

<210> 25
 60 <211> 1420
 <212> DNA
 <213> Human

 <400> 25
 65 gttcagcatt gtttctgctt ctgaaatctg tataatcacac tggtttgtaa tcattatgtc 60

ttcattgaaa tccttgctac ttctttcct cctcaatgaa agacacgaga gacaagagcg 120
 acacaagctt aagaaaaacg agcaaggaag agtatcttca ttattctcat tttctctgag 180
 ttggaaacaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 240
 agtggggaaaa ctttaagagt ttccacatat tagtttcat ttttgagtc aagagactgc 300
 5 tccttgact gggagacact agtagtatat gttgtatag ttactttaaa attatcttt 360
 tattttataa ggcccataaa tactggtaa actctgttaa aagtgggcct tctatcttgg 420
 atggttcac tgccatcagc catgctgata tattagaaat ggcaccccta tctacttact 480
 ttaatgctta aaattataca taaaatgctt tatttagaaa acctacatga tacagtggtg 540
 10 tcagccttgc catgtatcag tttcacttga aatttgagac caattaaatt tcaactgttt 600
 agggtgaga aagaggtact ggaaaacatg cagatgagga tatctttat gtgcaacagt 660
 atccttgca tgggaggaga gttactcttga aaggcaggc agcttaagt gacaatgtt 720
 tgtatatagt tgagaatttt acgacacttt taaaattgt gtaattgtt aatgtccagt 780
 tttgctctgt tttgcctgaa gttttagtat ttgtttctt ggtggacctc tgaaaaccaa 840
 15 accagtacct ggggaggtta gatgtgtt tcaggcttgg agtgtatgag tggtttgct 900
 tgtattttcc tccagagatt ttgaacttta ataattgcgt gtgtgtttt tttttttaa 960
 gtggctttgt tttttttctt caagtaaaat tgtgaacata tttcctttat agggcagg 1020
 catgagttag ggagactgaa gagtatttga gactgtacat gtgccttctt aatgtgttc 1080
 tcgacacatt tttttcagt aacttgaaaa ttcaaaaaggg acatttgggtt aggttactgt 1140
 20 acatcaatct atgcataaaat ggcagcttgc tttcttgagc cactgtctaa attttgttt 1200
 tatagaaaatt ttttatactg attggttcat agatggtcag tttgtacac agactgaaca 1260
 atacagcaact ttgccaaaaa tgagtgttagc attgtttaaa cattgtgtt taacacctgt 1320
 tctttgtaat tgggttgg tgcattttgc actacctgaa gttacagttt tcaatctgtc 1380
 agtaaataaa gtgtccttta acttcaaaaaa aaaaaaaaaa
 25 <210> 26
 <211> 689
 <212> DNA
 <213> Human
 30 <400> 26
 aaacaaacaa aaaaaaagtt agtactgtat atgtaaatac tagttttca atgtgctata 60
 caaacaatta tagcacatcc ttcctttac tctgtctcac ctcctttagg tgagtacttc 120
 35 cttaaataag tgctaaacat acatatacgg aacttgaaag ctttggtag cttgcctta 180
 ggtaatcagc ctagttaca ctgtttccag ggagtagttg aattactata aaccattagc 240
 cacttgtctc tgcaccattt atcacaccag gacagggtct ctcaacctgg ggcgtactgt 300
 catttggggc caggtgattt ttccttgcaaa gggctgtcct gtacctgccc gggggccgc 360
 tcgaagcgtg gtcgcggccg aggtactgaa aggaccaagg agctctggct gcccctcagga 420
 40 attccaaatg accgaaggaa caaagttca gggctctggg tgggtctcc cactattcag 480
 gaggtggtcg gaggttaacgc agttcattt cgtccagtc tttccagtt taaaagttgt 540
 tgtcaagatg ctgcattaaa tcaggcaggt ctacaaaggc atcccaagca tcaaacatgt 600
 ctgtgatgaa gtaatcaatg aaacacccga acctccgacc acctcctgaa tagtgggaga 660
 cacacccaga gcctgaagtt tgccttcg
 45 <210> 27
 <211> 471
 <212> DNA
 <213> Human
 50 <400> 27
 tcccagcggc atgaagtttgc agattggcca gcccctgtac ctgggcttca tctccttcgt 60
 ccctctcgct cattgggtgc accctgttt gcctgtctg ccaggacgag gcacccata 120
 55 agccctaacc caggccccgc ccagggccac cacgaccact gcaaacacccg caccctgccta 180
 ccagccacca gctgcctaca aagacaatcg ggccccctca gtgacctcgg ccaccacagc 240
 gggtagggc tgaacgacta cgtgtgagtc cccacagctt gtttctcccc tgggctgtc 300
 tgggctgggtt cccggccggc ctgtcaatgg aggcagggtt tccagcacaa agtttacttc 360
 tgggcaattt ttgtatccaa ggaataatg tgaatgcgag gaaatgtt taggcacag 420
 60 ggacagaggg ggaataaga ggaggagaaa gctctctata ccaaagactg a
 <210> 28
 <211> 929
 <212> DNA
 <213> Human
 65 <400> 28

5 ggtgaactca gtgcattggg ccaatggtc gacacaggct ctgccagcca caaccatcct 60
 gctgcttctg acggttggc tgctggtggg cttccccc actgtcattt gaggcatctt 120
 tggaaagaac aacgccagcc ccttgatgc accctgtcg accaagaaca tcgcccggga 180
 gattccaccc cagccctggt acaagtctac tgtcateccac atgactgtt gaggcttctt 240
 gcctttcagt gccatctctg tggagctgtt ctacatctt gccacagtat ggggtcggga 300
 gcagtagact ttgtacggca tccttctt tgccttcgat atccgtctga gtgtggggc 360
 ttgcattctcc attgcactca cctacttcca gttgtctggg gaggattacc gctgggtgg 420
 10 gcgatctgtg ctgagtttgc gctccacccg cctcttcattt ttccttctact cagtttctt 480
 ttatgcccg cgctccaaaca tgtctgggc agtacagaca gtagagttct tcggctactc 540
 cttaactcaact ggttatgtct tcttcctcat gctgggcacc atccctttt tttcttcctt 600
 aaagttcatc cggtatatct atgttaaccc caagatggac tgagttctgt atggcagaac 660
 tattgtgtt ctctccctt cttcatgccc tggtaactc tcctaccagc ttcttctgt 720
 15 attgactgaa ttgtgtatgc gcattgtgc ctccctttt tcccttggg cattccttcc 780
 ccagagaggg cctggaaatt ataaatctt atcacataag gattatataat ttgaactttt 840
 taagttgcct ttagtttgg tcctgatttt tcttttaca attacaaaaa taaaatttt 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa
 20 <210> 29
 <211> 1775
 <212> DNA
 <213> Human
 25 <400> 29
 30 gaacgtgtatg ggaactttgg gaggatgtct gagaaaaatgt ccgaaggat tttggccaac 60
 accagaaaaac gccaatgtcc taggaattcc ctcccaaaat gcttcccaaa aaattactca 120
 ttgacaattc aaattgcact tggctggcg cagcccgccg ggccttcagt ccgtgtggg 180
 cgcccgctg gccttcctt cgtaggactc cccaaactcg ttactctgc gtttatccac 240
 aggataaagc caccgttggt acaggttagac cagaaacaccc acgtcgccc ggaagcaggc 300
 cagccggta gacgtggca tggatgtatgaaaggcaac agtcatcaa tgaagggttt 360
 gaaaggctt taggtgaagg ccttccaggg cagatgtgcc actgacttca acttgttagt 420
 cacaagagc tggggcagca tgaagagggaa accaaaggca tagacccctg tgacgaagct 480
 gttgattaac caggagtacc agtcttata tttgtatattc agaggtaaat agacagcacc 540
 35 cccgacacag agagggtaca gcaggatgtca caagtacttc atggcctgag tattcgactc 600
 ctcggtttc ctctcagatt cgctgttaatg gccaaactga aattcggca tcaggcctct 660
 ccaaaaaata gtcatcttca atgccttctt cacttccac agtcaatgg cggctccaaac 720
 acccggccgg accagcacca gcaggctcgt ctgctcgcc agcaggaaca gaaagatgac 780
 cacgggtctg aagcagcgcc agagcaactgc cttgggtggac atgcccattca tgctttctt 840
 40 cttcttccag aaactgtatgt cattttaaa gcccaggaaa tcaaagagaa gatggAACgc 900
 tgcgacaaag aaggtcagecg ccaggaagta taagttgtt tctacaaaaa ttcccttcac 960
 ctcatcagca tctttctctg aaaaccgaa ctgctgcagg gagtacacgg cgtcctgcatt 1020
 gtggatccag aagcgcagcc gccccagtga gaccttgcgt taggacacgg tgaggggcag 1080
 45 ctcgggtgtt gagggtttt tgaccatcg gtccttcacg cgggtgtgt gctgggtcgat 1140
 gaacaggatg ggcaggtat gcacggttt ccccagctgg atcatcttca tgtaccgtat 1200
 cacatcgcc ggcaggagg acccgtaaa gacaaaggatg tccgcacatca cggtcagcgc 1260
 cagcccggtt cgccagtggtt acactggctc atccaggca ctcgtcggt tcttctccgc 1320
 ctcgatctgc tggatgtatcacttccgtt gagggttgg atttcttctg gcttggggac 1380
 catgttaggtg gtcagaggac tgaccaggatg cacctgttcc cctgtgtgcc acggcaggac 1440
 50 cccagcgtga tggaggaaga tggatgttca cagcgttccca ttgtttctgt ttttctttgg 1500
 tacagaaaaaca ttaactgtcc ttcaaaatggactccaca tcaaagtctt ccacattcaa 1560
 gaccaggtcg atgttgttct cagcaccatg gttggacccctc gtcgtgggtt acacgctcag 1620
 ctgcagcttgc ggccggccgc ccaggttaggg ctggatgcag ttggcgtcgcc cgagcacgg 1680
 55 gcccgggttagt acgatgcccgt acatgacccca gcaagggtgtgc accacgtaga ccacgaacac 1740
 gcccaccacc aagctggtaa aggagctgcg gcccc
 60 <210> 30
 <211> 1546
 <212> DNA
 <213> Human
 65 <400> 30
 aaaataagta ggaatggca gtgggttattt acatttacta cacctttcc atttgctaat 60
 aaggccctgc caggctggga gggaaattgtc cctgcctgct tctggagaaa gaagatattt 120

acaccatcta cgggcaccat ggaactgctt caagtgacca ttcttttct tctgcccagt 180
 atttcgagca gtaacagcac aggtgttta gaggcagcta ataattcaact tgggttact 240
 acaacaaaac catctataac aacacccaaac acagaatcat tacagaaaaa tgggtcaca 300
 ccaacaactg gaacaactcc taaaggaaca atcaccatg aattacttaa aatgtctctg 360
 5 atgtcaacag ctacttttt aacaagtaaa gatgaaggat tggaaagccac aaccactgat 420
 gtcaggaaga atgactccat catttcaaac gtaacagtaa caagtgttac acttccaaat 480
 gctgttcaa cattacaaag ttccaaaccc aagactgaaa ctcagagttc aattaaaaca 540
 acagaaaatac caggttagtgt tctacaacca gatgcacac tttctaaaac tggtacatta 600
 acctcaatac cagttacaat tccagaaaaac acctcacagt ctcaagtaat aggcaactgag 660
 10 ggtggaaaaa atgcaagcac ttcagcaacc agccggctt attccagttt tattttgccc 720
 gtgggttattt gtttggattgt aataacactt tcgttattt tttctgggtgg tttgtaccga 780
 atgtgctgga aggcagatcc gggcacacca gaaaatgaa atgatcaacc tcagtctgt 840
 aaagagagcg tgaagcttct taccgttaag acaatttctc atgagtctgg tgagcactct 900
 15 gcacaaggaa aaaccaagaa ctgacagttt gaggaaatctt ctccacaccc aggcaataat 960
 tacgcttaat cttcagcttc tatgcaccaa gcgtggaaaa ggagaaagtc ctgcagaatc 1020
 aatcccgact tccataccctg ctgctggact gtaccagacg tctgtcccac taaagtgtat 1080
 tccagctgac atgcaataat ttgtatggaa caaaaagaac cccggggctc tcctgttctc 1140
 tcacatttaa aaattccattt actccattt caggagcggtt cctaggaaaa ggaatttttag 1200
 20 gaggagaatt tggtagcagt gaatctgaca gcccaggagg tgggctcgct gataggcatg 1260
 actttccttta atgtttaaag tttccgggc caagaattttt tatccatgaa gactttccta 1320
 ctttctcggtt tttttttttt ttacctactt ttagtattttt ttgtttacca ctatgttaat 1380
 gcaggggaaaa gttgcacgtt tattttaaa tatttaggtt aaatcataacc atgctacttt 1440
 gtacatataa gtattttttt cctgcttctg tttttttttt aataaataac tactgtactc 1500
 aataactctaa aaatactata acatgactgt gaaaatggca aaaaaaa
 25 <210> 31
 <211> 750
 <212> DNA
 <213> Human
 30 <400> 31
 cacttggca ccccccattttt ctaaaaaaaat gggaaatctgg agggcaaaaaa aggtgtgctg 60
 35 aaggaaatg cctctgatgg cccaaaaacc ttcttccaaa ctatgttagg aatggatgg 120
 atagcaaatg gatccctttt ggcctccctt ggagcatgcc ttccctatct tattccttggc 180
 cccactaaag cagaacgtt cggatatttcc ttgttttgcc attggatgcc tatctggcca 240
 aacagccctt ccctaattgg aaaatgcagt cctgtttaaa acctttgatt tacgactact 300
 tgcacatgtt tgctcattttt aattttgaca ttttttacat agtgaagacc cccaaacatat 360
 40 cagtggaaaca tgacaagatc ataaagaaca gtatcatattt attattttgtt cgcttttaca 420
 gtggcaagcc aattttgaaa tatctcattt aaaactcaga cccaaattcac tgagtttatac 480
 ttttaatagc ttcctcagca cactatttcc catgcattttt atatgataaa ataatctatc 540
 actgcccattt ggtttttgtt aaaggaatgc tgaatacaga gcccacaaca cttttttttt 600
 tttttttttt acaaaatgtt acaatcatcaaa cacagacacg atttggactc cctgacaggt 660
 45 ggattggaaa acgggtttt aagagaagag aacattttaa cataaaatgtc attaagaatc 720
 cccaaaggccctt tatttgcac caccgtcccg
 <210> 32
 <211> 1620
 <212> DNA
 50 <213> Human
 <400> 32
 gcaattcccc cctcccaactt aacgactccc agtaattatg tttacaaccc attggatgca 60
 55 gtgcagccat tcataagaac cttgggtccc cagaaaaatc tttttttt ggtaccaac 120
 ctgagggtctt ttggaaagata atgttagaaaaa ccactaccta ttggatccctt gttttggctt 180
 atctgtgcaaa actctgatga tacctgcctt atgtggatcc tttccacac tttttttttt 240
 tttaagtata aagacttaga aaactagaat aatgttttta caaataatta aaagtatgtg 300
 atgttctggg tttttttttt cttttttttt ccccgctcc attttttttt tttttttttt 360
 60 aaaaaaaaaactt tttaacattt aaaaaataaa aatttacaaa atttcaactt ttccaggaca 420
 cgctggcattt tggactcaat gaaaaggca cctaaagaaa ataaggctga ctgaatgttt 480
 tccataattt tcacacaata acatccctt tctatccacg ttgccttcca tttatctctt 540
 gggtagctt ttccaggcaac atccctggcattt attggccaga aatgtacatgtg gctatcatgt 600
 attggaaatgg cacaggaaac cgaatcacat ggggtccctc cccttgggtt tcaagtatct 660
 65 tggagttgttgcac cccaaatggatgttgcac tttttttttt tttttttttt tttttttttt 720
 tgacaatcgatgttgcac tttttttttt tttttttttt tttttttttt tttttttttt 780

gtgttcctcc taggttggaa gaaatgttcc tccttctatc tgggtcctgt taaagcgggt 840
 gtcagttgtg tcttttcaacc tcgattttgtg aatataataga attggggggaa gagggaaatga 900
 tcatgtcaat taagtttcag gtttggcatg atcatcattc tcgatgatat tctcactttg 960
 tcgcaaatct gcccattatcg taagaacaag tttcagaatt ttcctccac tatacgactc 1020
 5 cagttattatg tttacaatcc attggatgag tgcagcatta taagaccttg gtgcccagaa 1080
 aaatctgtcc tttttgtac caaacctgag gtcttttggaa agataatgtaa gaaaaccact 1140
 acctattgaa ggcctgtttt ggctaattctg tgcaaactct gatgataacct gcttatgtgg 1200
 attctttcc acactgctt catttttaag tataaagact tagaaaacta gaataatgct 1260
 tttacaaaata attaaaagta tttttttttt cttttttttt agaaccctgt 1320
 10 atttaaacaac gccttctttt taagtcttgc ttgaaaatttta agtctcagat cttctggata 1380
 ccaaataaaa aacccaaacgc gtaaaacagg gcagtatttgc tttttttttt 1440
 tttatgtata ctctataaaat atagatgcat aaacaacact tcccttgag tagcacatca 1500
 acatacagca ttgtacatttta caatgaaaat gtgttaacttta agggattttt atatataaaat 1560
 acatatac ctttgtaacc ttttatactgt aaataaaaaaa gttgttttag tcaaaaaaaa 1620
 15 <210> 33
 <211> 2968
 <212> DNA
 <213> Human
 20 <400> 33
 gaaaaaagtag aaggaaacac agttcatata gaagtaaaag aaaaccctga agaggaggag 60
 25 gaggaggaag aagaggaaga agaagatgaa gaaagtgaag aggaggagga agaggaggga 120
 gaaagtgaag gcagtgaagg tttttttttt gatgaaaagg tttttttttt 180
 gggaaagacat tagataaaaaa gccaagtaaa gaaatgagct cagattctga atatgactct 240
 gatgtatgtc ggactaaaga agaaaaggct tatgacaaag caaaacggag gattgagaaa 300
 cggcgacttg aacatagtaa aatgttaaac accgaaaagc taagagcccc tattatctgc 360
 30 gtacttggc atgtggacac agggaaagaca aaaattcttag ataagctcg tcacacacat 420
 gtacaagatg gtgaagcagg tggtatcaca caacaaatttgc gggccacccaa tttttttttt 480
 gaagcttta atgaacacac taagatgatt aaaaattttt atagagagaa tttttttttt 540
 ccaggaatgc taatttttta tactccttgg catgaatctt tcagtaatct gaaaaataga 600
 ggaagcttc tttttttttt gttttttttt ttatgcattttt tttttttttt 660
 cagacaatttgc agtctatcaa ctttctcaaa tctaaaaat gttttttttt tttttttttt 720
 35 aataagatttgc atagtttata tgattttttt aagagtcttgc actctgtatgt ggctgtact 780
 tttttttttt tttttttttt tttttttttt tttttttttt 840
 gtagaattttttt cacagcaggg tttttttttt tttttttttt tttttttttt 900
 actttttttt tttttttttt tttttttttt tttttttttt 960
 tactttcttgc tagttttaac tcagaccatg ttgagcaaga gacttgcaca ctgtttttttt 1020
 40 ctgagagcac aggtgtatggaa gttttttttt tttttttttt tttttttttt 1080
 atcttgcattttttt tttttttttt tttttttttt 1140
 cccattttttt tttttttttt tttttttttt 1200
 aagaaccatgt atgaaaaatggaa taaagaatggaa gttttttttt tttttttttt 1260
 aaagaccttgc agaaaacatttggaa gttttttttt tttttttttt 1320
 45 atccctgttc tttttttttt tttttttttt tttttttttt 1380
 tttttttttt tttttttttt tttttttttt 1440
 tttttttttt tttttttttt tttttttttt 1500
 aaagatgttta tttttttttt tttttttttt 1560
 gccttcgtatg tttttttttt tttttttttt 1620
 50 atttttttttt tttttttttt tttttttttt 1680
 tttttttttt tttttttttt tttttttttt 1740
 atcctcccttc tttttttttt tttttttttt 1800
 gcaggtcagg tttttttttt tttttttttt 1860
 ggaatagttaa tttttttttt tttttttttt 1920
 55 gaagttttttt tttttttttt tttttttttt 1980
 tttttttttt tttttttttt tttttttttt 2040
 gactggttca tttttttttt tttttttttt 2100
 gtattttttt tttttttttt tttttttttt 2160
 gttttttttt tttttttttt tttttttttt 2220
 60 gacttaagttaa tttttttttt tttttttttt 2280
 aacttacactt tttttttttt tttttttttt 2340
 actcaccttc tttttttttt tttttttttt 2400
 cccaaatttttgc tttttttttt tttttttttt 2460
 gtactgcagg tttttttttt tttttttttt 2520
 65 acgttaagttaa tttttttttt tttttttttt 2580
 tttttttttt tttttttttt tttttttttt 2640

5 agctgcttg tgtgaaacca tgggtaaaa gcacagctgg ctgctttta ctgcttgtgt 2700
 agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaacaga 2760
 catccaccag taagcaagct ctgttaggct tccatggta gtggtagctt ctctcccaca 2820
 agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880
 5 ggtatgccag cacctggta acagtaggag atttataca ttaatctgat ctgttaatc 2940
 tgatcggtt agtagagatt ttatacat

10 <210> 34
 <211> 6011
 <212> DNA
 <213> Human

<400> 34

15

20 acggggcgcc ggacgacccg cacatcttat cctccacgcc ccactcgcac tcggagcggg 60
 accgccccgg actcccccgc gggccggcca ctcgaggagt gaggagagag gccgcccggc 120
 cggcttgagc cgagcgcagc acccccccgc ccccgcgcca gaagtttggt tgaaccgggc 180
 tgcgggaga aactttttc tttttcccc ctctcccggg agagtctctg gaggaggagg 240
 ggaactcccc cggcccaagg ctcgtggct cggggtcgcg cggccgcaga aggggcgggg 300
 tccgcccgcg aggggaggcg cccccggga cccgagaggg gggtgaggac cgcgggctgc 360
 25 tggtgcggcg gccgcagcgt gtgcggcg caggggaggc gccgccccgc tccggcccg 420
 gctgcgagga ggaggcggcg gccgcgcagg aggtatgtact tggtggcggg ggacaggggg 480
 ttggccggct gccggcacct cctggctctg ctgctggggc tgctgctgct gccggcgc 540
 tccggcaccc gggcgctggt ctgcctgccc tggacgagt ccaagtgcga ggagcccagg 600
 aaccggccgg ggagcatcgt gcagggcgctc tgccgctgtct gctacacgtg cgccagccag 660
 30 gggaaacgaga gctgcggcg caccggggg attacggaa cctgcgaccg gggctgcgt 720
 tggtcatcc gccccccgct caatggcgac tccctcaccg agtacgaagc gggcgtttc 780
 gaagatgaga actggactga tgaccaactg cttggttta aaccatgcaa tggaaacactt 840
 attgctggct gcaatataat caatggaaa tggatgtt acaccattcg aacctgcagc 900
 aatccctttg agtttccaag tcaggatatg tgcccttcag cttaaagag aattgaagaa 960
 gagaagccag attgctccaa ggcccgtgt gaagtccagt tctctccacg ttgtcctgaa 1020
 35 gattctgttc tgatcgaggg ttatgctcct cctggggagt gctgtccctt acccagccgc 1080
 tgcgtgtgca accccgcagg ctgtctgcgc aaagtctgcc agccggggaaa cctgaacata 1140
 ctagtgtcaa aagcctcagg gaagccggga gactgtgtg acctctatga gtcaaaacca 1200
 gtttcggcg tggactgcag gactgtggaa tgccctactg ttccagcagac cgctgtccc 1260
 ccggacagct atgaaactca agtcagacta actgcagatg gttgctgtac tttgccaaca 1320
 40 agatgcgagt gtctctctgg cttatgtgtt ttcccccgtgt gtggaggtgg atccactccc 1380
 cgcatagtct ctgcgtggcga tggacacact ggaaagtgtct gttatgtt tgaatgtgtt 1440
 aatgatacaa agccagcctg cgtatttaac aatgtggaaat attatgtgg agacatgttt 1500
 cgaatggaca actgtcggtt ctgtcgatgc caagggggcg ttgccatctg cttcaccgcc 1560
 cagttgggt agataaaactg cgagaggtac tacgtgcggg aaggagatg ctgcccagtg 1620
 45 tgtgaagatc cagtgtatcc ttttataat cccgctggct gctatccaa tggcctgatc 1680
 ctggccacg gagaccggtg gcgggaagac gactgcacat tctgcctgt cgtaacgg 1740
 gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaaccctgt gaaagtgcct 1800
 ggggagtgtt caaactgcac tctgacacgg aaggactgca ttaatggtt caaacgcgt 1860
 50 ggggagttt cacaatggtt gtcggacactg tcagtgcata aacacccagg aactatgttc agaacgtaaa 1920
 caaggctgca ctttgaaactg tcccttcgtt ttccttactg atgccccaaa ctgtgagatc 1980
 tgtgagtgtcc gcccaggccc caagaagtgc agacccataa tctgtgacaa gtattgtcca 2040
 cttggattgc tgaagaataa gcacggctgt gacatctgtc gctgtaaagaa atgtccagag 2100
 ctctcatgca gtaagatctg ccccttgggt ttcctgcagg acatgcacgg ctgtcttatac 2160
 55 tgcaagtgcg gagaggcctc tgcttcgtgt gggccaccca tcctgtcggt cacttgtctc 2220
 accgtggatg gtcatcatca taaaatgag gagagctggc acatgggtg cgggaatgc 2280
 tactgtctca atggacggga aatgtgtgcc ctgatcacct gcccggtgcc tgcctgtggc 2340
 aacccacca ttcaccctgg acagtgtgc ccatcatgtg cagatgactt tgggtgcag 2400
 aagccagagc tcagtactcc ctccatttgc cacgcctcg gaggagaata ctttggaa 2460
 60 ggagaaacgt ggaacattga ctccctgtact cagtgcaccc tccacagcgg acgggtgtc 2520
 tgtgagacag aggtgtgccc accgctgctc tgccagaacc cctcaacgcac ccaggattcc 2580
 tgctgcccac agtgtacaga tcaaccttt cggccttcct tggccgcac taacagcgta 2640
 cctaattact gcaaaaatga tgaagggat atattctgg cagctgatgc ctggaaaggct 2700
 gacgtttta ccagctgcat ctgcattgtat agcgttaatta gctgttctc tgagtcctgc 2760
 65 cttctgtat cctgtgaaag acctgtctt agaaaaggcc agtgtgtcc ctactgcata 2820
 aaagacacaa ttccaaagaa ggtgggtgc cacttcgtg ggaaggccta tgccgacgag 2880
 aaagacacaa ttccaaagaa ggtgggtgc cacttcgtg ggaaggccta tgccgacgag 2940

5 gaggcggtggg accttgacag ctgcaccac tgctactgcc tgcagggcca gaccctctgc 3000
 tcgaccgtca gctgcccccc tctgccctgt gttgagccca tcaacgtgga aggaagttgc 3060
 tgcccaatgt gtccagaaaat gtatgtccca gaaccaacca atataccat tgagaagaca 3120
 aaccatcgag gagaggttga cctggaggtt cccctgtggc ccacgcctag tgaaaatgat 3180
 atcggtccatc tcccttagaga tatgggtcac ctccaggtt tagattacagaga taacaggctg 3240
 caccctaaatg aagatttttc actggactcc attgcctcag ttgtggttcc cataattata 3300
 tgcctctcta ttataatagc attccctattc atcaatcaga agaaaacagt gataccactg 3360
 ctggctgtt atcgaacacc aactaaggct tcttccttaa ataatcagct agtatctgtg 3420
 gactgcaaga aaggaaccag agtccaggtg gacagttccc agagaatgct aagaattgca 3480
 gaaccagatg caagatttgc tggcttctac agcatgcaaa aacagaacca tctacaggca 3540
 gacaatttctt accaaacagt gtgaagaaag gcaacttagga tgaggttca aaagacggaa 3600
 gacgactaaa tctgctctaa aaagtaaaact agaatttgtg cacttgctt gtggattgtt 3660
 ttggattgtg acttgatgtt cagcgctaaag accttactgg gatgggctct gtctacagca 3720
 atgtgcagaa caagcattcc cactttctt caagataact gaccaagtgt tttcttagaa 3780
 ccaaagtttt taaagttgtt aagatatttt tgcctgttaa atagctgtt agatatttgg 3840
 ggtggggaca gtgagttgg atggggaaag ggggtggagg gtgggtttgg gaagaaaaat 3900
 tggtcagctt ggctcgggga gaaacctggt aacataaaag cagttcagtg gcccagaggt 3960
 tatttttttc ctattgtctt gaagactgca ctgggtgctt caaagctcag gcctgaatga 4020
 gcaggaaaca aaaaaggcct tgcgaccagg ctgccataac caccttagaa ctaccagacg 4080
 20 agcacatcag aacccttttga cagccatccc aggtctaaag ccacaagttt cttttctata 4140
 cagtcacaac tgcagtaggc agtgaggaag ccagagaaat gcgatagcgg catttctcta 4200
 aagcgggttta ttaaggatata atacagtttac actttttgtt gcttttattt ttttccaagc 4260
 caatcaatca gccagttcctt agcagagtca gcacatgaac aagatctaag tcatttcttg 4320
 atgtgagcac tggagctttt tttttttaca acgtgacagg aagaggaggg agagggtgac 4380
 25 gaacaccagg cattttccagg ggcttatattt cactgtttgt tggtgttttg ttctgttata 4440
 ttgttggttt ttcatagtttt ttgttgaagc tctagcttaa gaagaaactt ttttaaaaaa 4500
 gactgtttgg ggattttttt tccttattat atactgatttcc tacaaaatag aaactacttc 4560
 atttttaattt tatattttttt aagcacctttt gttgaagctc aaaaaaaaaatg atgcctcttt 4620
 aaacttttagc aattatagga gtattttatgt aactatctt tgcttcaaaa aacaaaagta 4680
 30 tttgtgttca tttgttatata atatatatat atacatatat atttatacac atacaattt 4740
 ttttttcttgc ttgaatgtat ttttatgaga ttttaaccag aacaaaggca gataaaacagg 4800
 cattccatag cagtgtttt gatcacttac aaatttttg aataacacaa aatctcattt 4860
 tacctgcagt ttaattggaa agatgtgtt gtgagagttt gtatgtgtt gtgtgtgtt 4920
 35 gtgtgtgcgc ggcacacgcac gccttgagca gtcagcattt cacctgctat ggagaagggt 4980
 attcctttat taaaatcttc ctcatttttttca gttgggttttca aatttgctca 5040
 ctggccagag acattgtatgg cagtttttca ctgcatttactt aatcagctcc tggatttttt 5100
 tttttttttt tcaaacaatg gtttggaaaca actactggaa tattgtccac aataagctgg 5160
 aagtttggttg tagtatgcctt caaatataac tgactgtata ctatagtgg aacttttcaa 5220
 40 acagccctta gcacttttat actaatttaccc ccatttgcattt attgagttttt ttttaaaaaa 5280
 tgcttgggtt gaaagacaca gataccagt atgcttacg tgaaaagaaa atgtgttctg 5340
 tttgttaaaag gaactttcaa gtattttgtt aaatacttgg acagaggttgc ctgaacttta 5400
 aaaaaaaaaattt atttattttt attatgaccc aatttatttttca tctgaagatt aaccattttt 5460
 ttgtctttaga atatcaaaaaa gaaaaagaaaaa aaggtgttttca agctgtttgc atcaaaggaa 5520
 45 aaaaaagattt attatcaagg ggcaatattt ttatcttttca caaaataaaat ttgttaatga 5580
 tacattacaa aaatagattt acatcagctt gattgtata aatttttttttca gtaatttac 5640
 cattcctggc ataaaaatgc tttatcaaaaaaaaatggtagt atgcttgc tttttttttt 5700
 caatcatggc catattatga aaatacttaccc aggtatagg acaagggttgc aattttttta 5760
 ttattttttt aaagatatga tttatcttgc gtgctgtatc tattactctt ttactttttt 5820
 tcctgttgggtt ctcttgcctt aaaaaaaaaat aatttgccttca agaataaaaat agatatatgg 5880
 50 cacttggagt gcatcatgt tctacagttt gtttttttttcaaaaaa agctgttaaga 5940
 gaattatcttgc caacttgattt cttggcagga aataaacattt ttgagttgaa atcaaaaaaaa 6000
 aaaaaaaaaaaa a

55 <210> 34a
 <211> 1036
 <212> DNA
 <213> Human

60 <400> 34a

55 <210> 34a
<211> 1036
<212> DNA
<213> Human

60 <400> 34a

65 mylvagdrgl agcghllvsl lgllllpars gtralvclpc deskceprn rpgsivqgvc 60
 gccytcasgg nescggtfgi ygtcdrglrc virpplingds lteyeagvce denwtddqll 120
 gfkpcnenli agcniingkc ecntirtcsn pfefpsqdmc lsalkrieee kpdcskarce 180
 vqfsprcped svlieqvapp qeccplpsrc vcnpagclrk vcqpgnlnil vskasgkpge 240

ccdlyeckpv fgvd crtvec ptvqqtacpp dsyetqvrilt adgcctlptr ceclsglcgf 300
 pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnv veyydgdmfr mdnccrfcrcq 360
 ggvaiacftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
 5 ctfcqcvnge rhcvatvcgq tctnpvkvpg eccpvceupt iitvdppacg elsnctltrk 480
 dcingfkrdh ncrtcqcin tqelcserkq gctlncpqf gtdaqnceic ecrprpkkr 540
 piicdkycpl g11knkhgcd icrckkcpel scskicplgf qqdshgclic kcreasasag 600
 ppilsgtclt vdghhhknee swhdgcrecy clngremcal itcpvpacgn ptihpgqccp 660
 scaddfvvqk pelstpsich apggeyfveg etwnidsctq ctchsgrvlc etevcppllc 720
 10 qnpsrtqdsc cpqctdqf pslsrnnnsvp nyckndegdi flaaeswkpd vctscicids 780
 viscfsescp svscerpvlr kgqccpycik dtipkkvvch fsgkayadee rwldlscth 840
 yclqqgtlcs tvscpplpcv epinvegsc pmpcpe myvpe ptnipiektn hrgevdlevp 900
 lwptpsendi vhlprdmghl qvdyrdnrlh psedsslldsi asvvvpiiic lsiiiaflfi 960
 nqkkqwipll cwyrtptkps slnnqlvsd ckkgtrvqvd ssqrmlriae pdarfsgfys 1020
 mqkqnhlqad nfyqtv
 15
 <210> 35
 <211> 716
 <212> DNA
 20 <213> Human

 <400> 35
 25 gcagtacctg gagtgcctg cagggggaaa gcgaaccggg ccctgaagtc cggggcagtc 60
 acccggggct cctggggcgc tctgggggc tggggcttag cagcgatcct gctttgtccc 120
 agaagtccag agggatcagc cccagaacac accctcctcc cgggacgcc gcagctttct 180
 ggaggcttag agaggcatga agagtggct ccacctgtg gccgacttag aaaaagaattt 240
 ccagaactcg gtcctatttt acagatttag aactatgtt tcaagaagag aggacggggc 300
 30 ttgagggaaat ctcctgattc tccttatatg acctcaaact gaccatacta aacagtgtag 360
 aaggctttt taaggctcta aatgtcaggg tctccatcc cctgatgct gacttgtaca 420
 gtcagtgtgg agtagacggg ttcctccacc cagggttgac tcaaggggat gatctgggtc 480
 ccattctggt cttaagaccc caaacaaggg tttttcagc tccaggatct ggagcctcta 540
 35 tctggtagt gtcgtaacct ctgtgtgcct cccgttaccc catctgtcca gtgagctcag 600
 ccccatcca cctaacaggg tggccacagg gattacttag ggttaagacc ttagaactgg 660
 gtctagcacc cgataagagc tcaataaatg ttgttcctt ccacatcaa aaaaaaa

 <210> 36
 <211> 395
 40 <212> DNA
 <213> Human

 <400> 36
 45 ccaatacttc atttttcatt ggtggagaag atttagact tctaaggatt ttccaaataa 60
 aaaagctatg atttgatttc caactttaa acattgcatt tccttgcca tttactacat 120
 tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180
 atgattatta cattgaaatc cttagccta tgtatattt cttaacttt gcactttcac 240
 50 gcccagtaaa accaaagtca ggttaaccaa tgtcatttt caaaatgtt aaaccctaat 300
 tgcagttcct ttttaaattt attttaaga ttacttaaca acattagaca gtgaaaaaaa 360
 agaagcaagg aaagcattct taattctacc atcct

 <210> 37
 <211> 134
 55 <212> DNA
 <213> Human

 <400> 37
 60 ccctcgagcg gcccgggg caggtacttt taccaccgaa ttgttcactt gactttaaga 60
 aaccctaaa gctgcctggc tttcagcaac aggcctatca acaccatggt gagtctccat 120
 aaggacacc gtgt

 <210> 38
 65 <211> 644
 <212> DNA

<213> Human

<400> 38

5 aagcctgtg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggttaggg 60
 cagtggcgct tgagttggtc gggggcagcg gcagattga ggcttaagca acttcttccg 120
 gggaaagatg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180
 ggaatattgg tgggccagca atcctcagac gcctcactta ggacaaatga gaaactgag 240
 gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaaggc acagccaaga 300
 10 ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagttt aggagaaaaga 360
 aggatgtta tggccagag gccagtcgtc cacatcagtgcagacatgatgaaaggcg 420
 ttcgcaccgg aaaatgttagc ttcccggta agtaccttgg ccatgttagaa gttgatgaat 480
 caagaggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagttct 540
 15 tcaaaggctt ctttgaaaaa actggaaaga aagcagttaa agcagttct gtgggtctaa 600
 gcagatggac tcagaggttg tggatgaaaaa actaaggacc tcat

<210> 39

<211> 657

<212> DNA

20 <213> Human

<400> 39

25 cttttgttt gggtttcca atgttagatgt ctcagtgaaa tggcagata tactttgttc 60
 cttatatggc caccagtgtt aattatggac aaatacatta aaaaacagggt tcctggccca 120
 gcctcccatc taatctttt gatactttt gatatctaact ctgaggagcg atttctgaat 180
 tagccagtgt tggccatctt ttctgttagg aattgttatta gaataaccc tcttttcag 240
 acctgctcag tgagacatct tggggatga agtagggaaaa tagacattt gttggaaaaac 300
 agaaaaatga gaacattaaa aagactcatt caagtatgag tataaaggc atggaaattc 360
 30 tggccctttt agcaaaaatga gaagaaaaaa ttctgctcag cagtatttac tggatgtt 420
 tttttgttt tttacacgaa tggaaaaatg atgtgttaatg ggtatagatt ttaatcagct 480
 aacagtcaatccagagattt tgatcagcac caattccat agtagtaatg attaaaaatg 540
 taagaaatac tactacattt aacattataa agtagatgtc tggacataac tggaaat 600
 atgtttgctt caatagaaaat ttgtccac ttgtatccc aacaaaatata tcggaaac

<210> 40

<211> 1328

<212> DNA

35 <213> Human

40 <400> 40

acaattttaa aataactagc aattaatcac agcatatcag gaaaaaagtac acagtggat 60
 45 ctggtagtt tttgttaggct cattatggtt agggtcgtt agatgtatata aagaacctac 120
 ctatcatgct gtatgtatca ctcattccat tttcatgttc catgcatact cgggcattcat 180
 gctaataatgt atcctttaa gcactctcaa ggaaacaaaa gggccttta tttttataaa 240
 ggtaaaaaaa attccccaaa tattttgcac tgaatgtacc aaaggtaag ggacattaca 300
 atatgactaa cagcaactcc atcacttgg aagtataata gaaaataatgt tctaaatcaa 360
 50 acttccttca cagtgcgtg tctaccacta caaggactgt gcatctaagt aataatttt 420
 taagattcac tatatgtat agttagatata gcatattttt aaaaatgcatt agactcttt 480
 ccatccatca aataactttac aggtggcat ttaatacaga tatttcgtat ttccccact 540
 gcttttttatt tggatcagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600
 tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaattgaa 660
 actcagaact atatttctaa gcctgcattt tcactgtatc ataattttct tagtaatatt 720
 55 aagagacagt ttttctatgg catctccaaa actgcattgac atcactagtc ttacttctgc 780
 ttaattttat gagaaggtat tcttcatttt aattgcattt gggattactc cacatctt 840
 tttattttctt gactaatcag attttcaata gagtggat 900
 atttttttttt gatgtttttt gggatgtttt gggattactc cacatctt 960
 tgagatctat atttataatgc agccatggaa ttccattttt gggatgtttt gggatgtttt 1020
 60 ttttatagag gtcatatgc tagtttcat aggtgtttt 1080
 gtgagttaaatg ctatgtttac tactgggacc ctcaagagga ataccactt tgatcactc 1140
 ctgcactaaa ggcacgtact gcagtgtaa gaaatgttct gaaaaagggt tatagaaatc 1200
 tggaaataag aaaggaagag ctctctgtat tctataattt gaaagaaaaaa aaaaac 1260
 ttttaactgg aaatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
 65 tgaaaaaaa

<210> 41
 <211> 987
 <212> DNA
 <213> Human
 5 <400> 41

 aacagagact ggcacaggac ctcttcattt caggaagatg gtagtgttagg caggttaacat 60
 ttagctctt tcaaaaaagg agagctttc ttcaagataa ggaagtggta gttatggtgg 120
 10 taaccccccgg ctatcagtcc gtaggttgc cacccttcct gctgttaggat ggaagcagcc 180
 atggagtggg agggaggcgc aataagacac ccctccacag agcttggcat catggaaagc 240
 tggtttctacc tcttcctggc tcctttgtt aaaggcctgg ctgggagcct tcctttggg 300
 tgtcttcctc ttctccaacc aacagaaaaaactgctttc aaaggtggag ggtcttcattg 360
 15 aaacacagct gccaggagcc caggcacagg gctgggggccc tgaaaaagg agggcacaca 420
 ggaggaggga ggagctggta gggagatgct ggcttaccc aaggtctcga aacaaggagg 480
 gcagaatagg cagaggcctc tccgtcccag gcccattttt gacagatggc gggacggaaa 540
 tgcaatagac cagcctgcaa gaaagacatg tgttttagt acaggcagtg tggccgggtg 600
 gaacaagcac aggccttggaa atccaatggatcgaatcaga accctaggcc tgccatctgt 660
 cagccgggtg acctgggtca atttttagcct ctaaaagcct cagtctcctt atctgcaaaa 720
 20 tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggtatccaa 780
 aatagtctac ggccatacca ccctgaacgt gcctaatttc gtaagctaag cagggtcagg 840
 cctggtagt acctggatgg gtagatgatg gaaaacatac ctgcccgcag ttggagttgg 900
 actctgtctt aacagtagcg tggcacacag aaggcactca gtaaataactt gttgaataaaa 960
 tgaagtagcg atttgggtgtg aaaaaaaa
 25 <210> 42
 <211> 956
 <212> DNA
 <213> Human
 30 <400> 42

 cgacgggtgg ggcggacgcg tgggtgcagg agcagggcgg ctggccactg ccccaaccaa 60
 ggaaggagcc cctgagtccg cctgcgcctc catccatctg tccggccaga gccggcatcc 120
 35 ttgcctgtct aaagccttaa ctaagactcc cgccccggc tggccctgtg cagaccttac 180
 tcaggggatg tttacctggt gctcgggaag ggaggggaag gggccggggg gggggcacgg 240
 caggcgtgtg gcagccacac gcaggcggcc agggcggcca gggacccaaa gcaggatgac 300
 cacgcacctc cacgccactg cctccccga atgcatttgg aaccaaagtc taaactgagc 360
 tcgcagcccc cgcccccctcc ctccgcctcc catcccgctt agcgctctgg acagatggac 420
 40 gcaggccctg tccagcccc agtgcgctcg ttccggtccc cacagactgc cccagccaaac 480
 gagattgctg gaaaccaagt caggccaggt gggcggacaa aaggccagg tgccgcctgg 540
 ggggaacgga tgctccgagg actggactgt tttttcaca catcggtgcc gcagcggtgg 600
 gaaggaaagg cagatgtaaa tgatgttttgcgtt gtttacaggg tatatttttgcgtt 660
 tgaattaatt cagatgtttt acgcaaggaa ggacttaccc agtattactg ctgctgtgct 720
 45 tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcgggtg accccatcac 780
 tcgcaggacc aaggggcgg ggactgctgg ctcacgcccc gctgtgtcct ccctccctc 840
 cttcccttgg gcagaatgaa ttcgatgcgt attctgtggc cgccatctgc gcagggtgg 900
 ggtattctgt cattacaca cgtcggttca attaaaaagc gaattataact ccaaaaa
 50 <210> 43
 <211> 536
 <212> DNA
 <213> Human
 55 <400> 43

 aaataaaacac ttccataaca ttttgttttca gaagtctatt aatgcaatcc cactttttc 60
 cccctagttt ctaaatgtt aagagagggg aaaaaaggct caggatgtt ttcacccatc 120
 agtgttagct gtctttatt ttactcttgg aaatagagac tccatttaggg ttttgcatt 180
 60 ttgggaaccc agtttacca ttgtgtcagt aaaacaataa gatagttga gagcatatga 240
 tctaaataaa gacatttggaa gggtagttt gaattctaaa agtaggtat agccaaatag 300
 cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaatttagaaa agtgaaaat 360
 atttttcca gatgaaactt gtgccacttc caattgacta atgaaataca aggagacaga 420
 ctggaaaaag tgggttatgc cacctttaaa accctttctg gtaaatatta tgtagctaa 480
 65 aqqtgtgttt ccccgccacc tggaccttggc caggttagggt tccgtggta accagt

<210> 44
 <211> 1630
 <212> DNA
 <213> Human

5
<400> 44

ggggagggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60
 gctccctggg caccaagtcc caggcaggag cagctgttt ccatcccttc ccagacaagc 120
 10 tctatttttta tcacaatgac cttagagag gtctcccagg ccagctcaag gtgtcccact 180
 atcccctctg gagggaaagag gcagggaaat tctccccggg tccctgtcat gctactttct 240
 ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
 gtgatttccc ttaggcccag gacttgggcc tccagctcat ctgttccttc tggcccccatt 360
 catggcaggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
 15 gactttaccc tattgccttc agtttgggt tgcttattgg gaaagagaga gacaaagagt 480
 tacttggttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
 gacaggattg gctcagatga cccctgaggg ctcttccagt cttgaaatgc attccatgtat 600
 attaggaagt cgggggtggg tgggtgggt gggctagttt ggtttaatt taggggcccga 660
 20 tgagcttggg tacgtgagca ggggtttaag ttagggctcg cctgttatttc tggtcccctt 720
 ggaaatgtcc ctttcttcag tgcagacact cagtcaggat gtccatatcg tgcccagaaa 780
 agtagacatt atcctgcccc atcccttccc cagtcactc tgaccttagt agtgcctgg 840
 gcccagtgac ctgggggagc ctggctgcag gccctcactg gttccctaaa ccttgggtggc 900
 tgtgattcag gtccccaggg gggactcagg gaggaatatg gctgagttct gtagttcca 960
 25 gagttggctg gtagagcctt ctagaggatc agaatattag cttcaggatc agctgggggt 1020
 atggaattgg ctgaggatca aacgtatgtt ggtgaaagga taccaggatg ttgctaaagg 1080
 tgagggacag tttgggtttt gggacttacca ggggtatgtt agatctggaa cccccaagtg 1140
 aggctggagg gagttaaagg tcatatggaa gatagggtt ggcacagggtt ctttggatg 1200
 aaagagtgac ctttagagggc tccttggcc tcaggaatgc tcctgctgt gtgaagatga 1260
 30 gaaggtgctc ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320
 ctgggtccct ttagcacag gagactgggg ctaaggcccc ctcccaggaa agggacacca 1380
 tcaggectct ggctgaggca gtagcataga gatccattt ctacctgcat ttcccagagg 1440
 actagcagga ggcagccctt agaaaccggc agttcccaag ccagcgccctg gctgttctct 1500
 cattgtcaact gcccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560
 cctcttgcctt cttgtagaat gcaagctctgg ccctcaataa atgcttcctg cattcatctg 1620
 35 caaaaaaaaaa

<210> 45
 <211> 169
 <212> DNA
 40 <213> Human

<400> 45

tcttttgctt ttagctttt atttttgtat taacaggagt cttattacac ataggtctga 60
 45 taaaactgggt ttatgatctt cagtcgttccat ccagtgtgc ataacttagat aacgtatgaa 120
 ggaaaaacga cgacgaacaa aaaagtaagt gtttggaaaga cttagttga

<210> 46
 <211> 769
 50 <212> DNA
 <213> Human

<400> 46

55 tgcaggtcat atttactatc ggcaataaaaa ggaagcaaag cagtattaag cagcggtgga 60
 atttgtcgct ttcactttt ataaagtgtt acataaaaatg tcataattcc aaattttaaaa 120
 acataactcc agttcttacc atgagaacacat caggtgtatc acgaaggatc ttcttggaaa 180
 aaacaaaaac aaaaacaaaaa aacaatgtatc tcttctgggt atcacatcaa atgagataca 240
 aaggtgtact aggcaatctt agagatctgg caacttattt tataatataag gcatctgtga 300
 60 ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataaatgtat taaaatgcaag 360
 cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
 ggccagctcc tttcctgata gtctgattct gccttcataat ataggcagct cctgatcatc 480
 catgccatgt aatgagaaaaa caagcatgga atataaaaaac ttttacatcata aaaaatgttt 540
 tattttgtaa taaaatcaaa tttccatttgg aaaccttcaa aaactttgca gaatgagggtt 600
 65 ttgatatatg tgtacaagta gtaccttctt agtgcagaa aacatcatta tttctgtctg 660
 cctgcctttt tgttttaaa aatgaagact atcattgaaa caagttgtc ttcagtatca 720

ggacatgttg acggagagga aaggtaggaa agggttaggg atagaagcc

<210> 47

<211> 2529

5 <212> DNA
<213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatcac tttcacaaca 60
gtaaaaatta gtgactggtt aagggtgtcc actgtacata tcatttcattt ctgactgggg 120
tcaggacctg gtcctagtcc acaagggtgg caggaggagg gtggaggcta agaacacaga 180
aaacacacaa aagaaaggaa agctgcctg gcagaaggat gaggtggtga gcttgcgag 240
ggatggtggg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
15 gccttactta gtcctggca gagggtgagt ggggacctac gagttcaaa atcaaatggc 360
atttggccag cctggctta ctaacaggtt cccagagtgc ctctgttggc tgagctctcc 420
tgggctcaact ccatttcattt gaagagtcca aatgattcat tttcttaccc acaactttc 480
attattcttc tggaaaccca tttctgtga gtccatctga cttaagtccct ctctccctcc 540
20 actagttggg gccactgcac tgagggggtt ccaccaatt ctctctagag aagagacact 600
ccagaggccc ctgcaacttt gcggatttcc agaagggtat aaaaagagca ctcttgagt 660
ggtgcggcagg aatgtttaaa atctatcagg cacactataa agctgggtt ttcttcctac 720
caagtggatt cggcatatga accaccaact caatactta tattttgtct gtttaaacac 780
tgaactctgg tggacagg tacaaggag aagagatgg gactgtgaag aggggaggc 840
25 ttccctcatc ttccctcaaga tctttgttcc cataaactat gcagtataaa ttgagaaaaa 900
gcaatagatg gggcttccta ccatttgggtt gttattgtcg gggtagcca ggagcagtgt 960
ggatggcaaa gtaggagaga ggcccagagg aaagcccatttccctccagc tttgggtct 1020
ccagaaagag gctggatttc tggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
aggtaacag tcctacactgc ttggtaccat agtccctcaa taagattcag aggaagaagc 1140
ttatgaaact gaaaatcaaa tcaaggattt gggagaata attcccttc gattccacag 1200
30 gagggaaagac cacacaatat cattgtgtcg gggctccca agggcctgccc acctggctt 1260
acaaatcatc aggggttgcc tgcttggcag tcacatgtt ccctggttt agcacacata 1320
caaggagttt tcagggaaact ctatcaagcc ataccaaaat cagggtcaca tgggtttc 1380
cccttcctt gcctcttcattt aaaaagacaac ttggcttcgtt aggtgggtgg tctttgtcat 1440
gcagttggc tgacctgaca aagccccag ttccctgtgg caggttctgg gagaggatgc 1500
35 attcaagctt ctgcagccata ggggacaggctgctt agtattact gcctcggagc 1560
tccaaatccc accaaagtcc tgactccagg tctttcttaa tgacatgttgc tcaatctcag 1620
cttcggcagt attctcggtt gtatgttctc tggcagagag aggcagatga acatagttt 1680
agggagaaaag ctgatggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
tgccagggaaa ccaggaagtc attcaagttt ttctctgagg ccaaagacac tgagcacagc 1800
40 ccagagccaa taaaagatct ttgagtctt ggtgaattca cgaagtgacc ccagctttag 1860
ctactgcaat tatgatttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
gggggagtgg gggggaaagg aaagagaaca gagcggcact gggatttggaa aggggaacct 1980
ctctatctga ggagccccca ctggcttcag aagcaactta ccaagggtt tttaaagaca 2040
tgaaaatttc cagaaatacc atttggtgca tccctttgtt tctgtaatat taaaactcagg 2100
45 tgaaaattata ctctgacagt ttctctctt ctgcctcttc cctctgcaga gtcaggac 2160
gcagaactgg ctgaaacaaat atttcatgtt gtcacccatg agagatgact caatgccaag 2220
gcctgaagtt atagagtgtt tacagcggtt gcgatattca ggggtcatcg ccaactggc 2280
tcgagttcca aagctctgat gaagaaacaa gactccttga tggttactg atcccactga 2340
50 ttccaggagt caagattagc caggaagccaa aacaccagga gttgggtgg cacgtcacca 2400
gtccagagcc ctgcccacggta tggacgcagg agcccagcat taggcaatca ggagccagaa 2460
catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgccacatacc 2520
gggggtgtcc

<210> 48

55 <211> 1553

<212> DNA

<213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatataattt 60
ttcatatata tatatacata catatataaa gaaaacaatt tgcaaattta cacacctgac 120
aaaaccatata atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
ctagccagggc ccgtttcca tcccttaagta catttccttc atttggccc ttcttaggg 240
65 gggccctga gcttggttt tagaagttt gtcataat aaccatagct ttaatcccc 300
tgaaggacag tggatgacccatc atctttgtct gtcggccatg ttacgtat 360

5 ccatcaagag ggctatggga gccaaatgaa cacggggat tgaggcta at tcacctgaac 420
 tcgaaaacag cgcccagctt cctcaccgca ggacacgcgc tttctttt ttttctcg 480
 gacggagtct cgctgtttg cccaggctgg agtgcagtgg cacggctcg gctactgca 540
 agctccacct cctggattca taccatttc ctgcttcagc cttccgagta gctggacta 600
 taggtgccaa ccaactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660
 10 caccgtgtta gccaggatgg tctcgctcg actttgtat ccggccgcct cggcctccca 720
 aagtgcgtggg attacaggcg tgagccacca cacctggccc cggcacgtat ctttaagga 780
 atgacaccag ttctcgctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 agacaggagg gtggtggcag caacactgca gctgcttcg gatgctgctg gggtgctc 900
 15 cgagcgggt gtgaacacgcg cacttcaaca tgagcaggcg cctggctccg gtgtgtc 960
 acttcagtgg tgcacctgga tggtggaaagc cagccttgg ggcaggaaac cagctcagag 1020
 aggctaccca gctcagctgc tggcaggagc caggtattta cagccataat gtgtgtaaag 1080
 aaaaaacacg ttctgcaaga aactctcta cccgctcg 1140
 20 gnatgagctt cactcaacgt ggagatggtg gtggactggc cctgaaaag cgggccttgc 1200
 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260
 cgagggggcaggcaggcgttcc tctctagtc ctttggaggc tttggctgag agaagagtga 1320
 gcagggagct gggatggc caggcaggga agggagctga agtatttcgg ggctaatgcc 1380
 tcagatcgat gtatttctct ccctggctc ccggagccct cttgtcaccg ctgctgc 1440
 gcaggaggcc catctcttct gggagctt ctgacttaac ttcaactaca agttcgctct 1500
 tacgagacccg gggtagcgt gatctcctgc ttccctgagc gcctgcacgg cag

<210> 49

<211> 921

<212> DNA

25 <213> Human

<400> 49

30 ctgtggtccc agctactcag gaggctgagg cgggaggatt gctttagccc aggagttgg 60
 tttgcagtg agccaaatgc gcaccattgc cttccactt gggccacgga gcaataacc 120
 gtctcagaaa acaaacaaca aaaagcagaa acgctgaagg ggtcggtta cgggaaaacc 180
 gcctgtcaga acacttggct actcctaccc cagatcagt gacctggaa tgagggttgg 240
 tcccgggagg ctttctcca agctgttgc accagacccg ccatggaaac cctggccaca 300
 35 gaaggctccc ggggagtgag ccagacctg gaccgctgtg ctgtatgtc tgggtggag 360
 ggaggggtggg gagtgtgaa gggtgtgtgt gtcccgggg ggtgttcatg ggcaagcatg 420
 tgcgtgcctg tttgtgtgcg tgccctccc ctgcagccgt cgggtgtatc tccctccagc 480
 cccttcgcca ctttctgagc attgtctgtc cacgtgagac tgcccagaga cagcagagct 540
 ccacgtgggtt ttaagggag acctttccct ggacctgggg gtctcgccgt atctcatgac 600
 40 caggtctaa atgacccgac atgcattcacc tgccttcga tgaccaacct ccctgtcccc 660
 gtcccgctga cttccccccg tggcgctca cggtgatgcc tgctctgtac attgggttgc 720
 actgtgcaaa actacattct ggtggaaat ttcatgtac atgtgtggca tggaaaat 780
 ttcaataaaa atggacttga tttagaaaagc caaaaagctg tgggtccctt ccagcacgga 840
 tactttgacc tcttgcctac aacccttcc ttgggtccga ggctggtagc ttgttca 900
 tcagatgggtt gggggcggtt g

45

<210> 50

<211> 338

<212> DNA

<213> Human

50

<400> 50

atgatctatc tagatgcctt accgtaaaat caaaaacacaa aaccctactg actcattccc 60
 55 tcccttccag atattacccc atttctctac ttcccattgt agccaaactt tccaaaaatt 120
 catgttctgt ctcatttcc tcattttca cccaccctgt ctttagctacc acccctcagt 180
 aacgacctag cctgggtaga aacaaatgtc agcatgatac catactcaat gatccttcgt 240
 cactgttgc attgtcatca ttccatggcc ttactttccc tctcagcgc 300
 gtaagaaact ttctttctt aattcttggt tctcttgg

60

<210> 51

<211> 1191

<212> DNA

<213> Human

65

<400> 51

ctagcaagca ggttaaacgag ctttgtacaa acacacacag accaacacat ccggggatgg 60
 ctgtgtgtt ctagagcaga ggctgattaa acactcagt tttggctct ctgtgccact 120
 cctggaaaat aatgaattgg gtaaggaaca gtaataaga aatgtgcct tgctaactgt 180
 5 gcacattaca acaaagagct ggcagctcct gaaggaaaag ggcttgc gctccgttc 240
 aaacttgtca gtcaactcat gccagcagcc tcagcgtctg cttcccccac acaccctcat 300
 tacatgtgtc tttctggcct gatctgtca tctgctcga gacgctcctg acaagtccgg 360
 aatttctcta tttctccact ggtcaaaaga gcccatttct ccctgctct cttctgtcac 420
 ccccgtcct cttcccccagg aggctcctt attatggta gcttggact tgcttccccg 480
 tctgactgtc cttgacttct agaatggaa aagctgagct ggtgaaggaa agactccagg 540
 10 ccatcacaga taaaagaaaa atacaggaag aatctcaca gaagcgtctg aaaatagagg 600
 aagacaaact aaagcaccag catttgaaga aaaaggcctt gaggagaaa tggcttctag 660
 atggaatcag cagcggaaaaa gaacaggaag agatgaagaa gcaaaatcaa caagaccagc 720
 accagatcca ggttctagaa caaagtatcc tcaggcttga gaaagagatc caagatctt 780
 15 aaaaagctga actgcaaattc tcaacgaagg aagaggccat tttaaagaaa ctaaagtcaa 840
 ttgagcggac aacagaagac attataagat ctgtgaaagt ggaaagagaa gaaagagcag 900
 aagagtcaat tgaggacatc tatgctaata tccctgaccc tccaaagtcc tacatacctt 960
 cttagttaaag gaaggagata aatgaagaaa aagaagatga tgaacaaaat aggaaagctt 1020
 tatatgcccattt gaaattaaa gttaaaaag acttgaagac tggagaaagt acagttctgt 1080
 20 cttccaatac ctctggccat cagatgactt taaaaggtac aggagaaaa gtttaagatg 1140
 atggcaaaa gtccagtgtt ttcagtaaag tgctaattcac aagttggagg t

<210> 52
 <211> 1200
 <212> DNA

25 <213> Human

<400> 52

aacagggact ctcactctat caaccccagg ctggagtccg gtgcgcac cctggctccc 60
 30 tgcaacctcc gcctcccagg ctcagcaac ttcctgcct cagtcgtct agtagctgg 120
 actacaggca cacaccacca tgcccagcca atttttgcatttttgcata gacagggttt 180
 cgccttctgt ccaggccggc atcatatact ttaaatcatg cccagatgac ttaataacct 240
 aatacaat atcaggttgg tttaaaaata attgctttt tattatttt gcattttgc 300
 accaacctta atgctatgtt aatagtgtt atactgtgc ttaacaacag tatgacaattt 360
 35 ttggctttt cttgttattt tttttttttt ttgtgtggc tttttttttt 420
 ttctcagtgtt tttcaatttcc tccttgggtt aatccatgga tgcaaaaccc acagatatga 480
 agggctggct atatatgcattt tgatgattgt ctttattat tagttataaa gtgtcattt 540
 atatgtatgtt aaagtatgg tacagtggaa agagtagttt aaaaacataaa catttggacc 600
 tttcaagaaaa ggttagcttgg tgaagttttt caccttcaaa ctatgtccca gtcagggctc 660
 40 tgctactaat tagctataat tttgcacaa attacatcac ctttgagttt cagttgcctc 720
 acctgtaaaaa taaaagaact ggataactctc taaggtcact tccagccctg tcattttata 780
 actctgttat gctgaggaag aaatttcacat tttttttttt ttgtgtggc tttttttttt 840
 gattattaaa gtggaaaaaa gccaattgtt tttttttttt agctcaacta aatttggaaa 900
 45 gaataatctt ttcaattttt taagaatttta aatatttttta agggtttgc ctattttttt 960
 agagatgggg tctcactctg tcacccagac tggagttacag tggcacaatc atagctact 1020
 gctgcctcaa attcatgggc tcaagtgttccctc tgcctccaga gtagctgcga 1080
 ctatggcat gtgccaccac gcctggctaa catttgcattt gacctattttt ttattttgtt 1140
 tttatatctt tttttttttt tttttttttt aatcagaaat acttattttt 1200

50 <210> 53
 <211> 989
 <212> DNA
 <213> Human

55 <400> 53

aagccaccac tcaaaaacttc ctatacattt tcacagcaga gacaagtggaa cattttttt 60
 tatgcctttc ttcctatgtt tatttcaagt ctttttcaaa acaaggcccc aggactctcc 120
 gattcaatta gtccttgggc tggtcactg tgcaggagtc cagggagctt ctacaaatgc 180
 60 agagtgactc tttaccaaca taaaccctag atacatgcaaa aagcaggac cttccctcca 240
 ggaatgtgcc atttcagatg cacagcaccc atgcagaaaa gctggattt tccttggaaac 300
 cgactgtgtt agaggtgctt acatgaacat tgctactgtc tttttttttt tttgagacag 360
 gtttcgttgc tgcccgaggct gaggtaatg cgtgatctca ctcactgcaaa ttccaccc 420
 aggttcaagc attctctgc tcagcctcct agtagctggg ttacaggcac tgccaccatg 480
 65 ccggcttaattt ttgtattttt ttagagatgg atttctccat ttggcaggc ggtctcgaaac 540
 cccaaacctca gtgatctgcc acctcagcct cctaagtgtt ggattacagg atgagccacc 600

5 cgaccggcca ctactgtctt tctttgaccc ttccagttc gaagataaaag aggaaataat 660
 ttctctgaag tacttgataa aatttccaaa caaaacacat gtccacttca ctgataaaaa 720
 atttaccgca gttggcacc taagagtatg acaacagcaa taaaaagtaa tttcaaagag 780
 ttaagattc ttcagcaaaa tagatgattc acatcttcaa gtccttttgg aaatcagtta 840
 ttaatattat tcttcctca tttccatctg aatgactgca gcaatagttt tttttttt 900
 tttttttt ttgcgagatg gaatctcgct ctgtcgccca gcgggagtgc actggcgcaa 960
 gcccggctca ccgcaatctc tgccacccg

10 <210> 54
 <211> 250
 <212> DNA
 <213> Human

15 <400> 54
 15 catttccca ttggcctga tggtaaagat ttagttaaag aggctgttaag tcagggtcg 60
 gcagaggcta ctacaagaag taggaaatca agtccctcac atgggttattt aaaaacttagt 120
 agtgggtggag tagtggaaaaaa gaaatctgag caacttcata acgtaactgc ctttcaggga 180
 20 aaagggcatt ctttaggaac tgcattctgtt aacccacacc ttgatccaag agctaggaa 240
 acttcagttg

<210> 55
 <211> 2270
 <212> DNA
 25 <213> Human

<400> 55
 30 gcgcgcgcgc gcagcgcccc cgccctccgc gccttctccg cgggacctc gagcgaaaga 60
 ggcccgcgcg ccgcgcgcgc ctcgcctccc tgcccaccgg gcacaccgcgc cggccacccc 120
 gaccccgctg cgcacggcct gtccgctgca caccagctt tggtcgctt cgtcgccgc 180
 ctcgcggccgc gctactcctg cgcgcacaa tgagctcccg catgcgcagg ggcgcgcct 240
 tagtcgtcac ctttctccac ttgaccaggc tggcgctctc cacctgcggc gtcgcctgccc 300
 actgcgcgcgc ggaggcgccc aagtgcgcgc cgggagtcgg gtcggccgg gacggctgc 360
 35 gctgctgtaa ggtctgcgc aagcagctca acgaggactg cagcaaaacg cagccctgc 420
 accacaccaa ggggctggaa tgcaacttcg ggcgcacatc caccgctctg aagggatct 480
 gcagagctca gtcagaggcgc agaccctgtg aatataactc cagaatctac caaaacgggg 540
 aaagtttcca gccaactgt aaacatcagt gcacatgtat tgatggcgcgtt gtcggctgc 600
 ttcctctgtg tccccaaagaa ctatcttcc ccaacttggg ctgtcccaac ctcggctgg 660
 40 tcaaagttac cgggcagtgc tgcgaggagt gggctgtga cgaggatagt atcaaggacc 720
 ccatggagga ccaggacggc ctccttggca aggagcttgg attcgatgcc tccgagggtgg 780
 agttgacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcactg aagcggctcc 840
 ctgttttgg aatggaggcct cgcacatctt acaaccctt acaaggccag aaatgtattt 900
 ttcaaaacaac ttcatggtcc cagtgctcaa agacctgtgg aactggatc tccacacgag 960
 45 ttaccaatga caaccctgag tgccgcctt tgaaagaaac cccgattttt gaggtgcggc 1020
 cttgtggaca gccagtgtac agcagcctga aaaagggcaa gaaatgcagc aagaccaaga 1080
 aatccccca accagtcagg tttacttacg ctggatgtt gagtgtaag aaataccggc 1140
 ccaagttactg cggccctgc gtggacggcc gatgctgcac gcccagctg accaggactg 1200
 tgaagatgcg gttccgcgtc gaagatgggg agacattttt caagaacgtc atgatgtacc 1260
 50 agtcctgcaa atgcaactac aactgcggc atgcaatga agcagcggtt cccttctaca 1320
 ggctgttcaa tgacattcac aaatttaggg actaaatgtc acctgggtt ccagggcaca 1380
 cctagacaaa caagggagaa gagtgctaga atcagaatca tggagaaaat gggcgggggt 1440
 ggtgtgggtg atgggactca ttgtagaaag gaagccttgc tcattcttgc ggagcattaa 1500
 55 ggtatttcga aactgccaag ggtgctggc cggatggaca ctaatgcagc cacgatttgc 1560
 gaataactttg cttcatagta ttggagcaca ttgtactgtc tcattttggc gcttggag 1620
 ttgtatgactt tctgttttgc ttgttaat tatttgcata gcatttttgc tctaggctt 1680
 tttccttttgc gggttctaca gtcgtaaaag agataataag attagttggc cagtttaag 1740
 cttttatttgc tcctttgaca aaagtaatg ggagggcatt ccatcccttc ctgaaggggg 1800
 acactccatg agtgcgtgtg agaggcagct atctgcactc taaactgcaaa acagaaatca 1860
 60 ggtgttttgc gactgaatgt ttattttatc aaaatgtac ttttggggag ggagggggaaa 1920
 tgtaatactg gaataatttg taaatgattt taattttata ttcaatgtaaa agattttattt 1980
 tatggattt accatattaa aaagaaatat ttacctaata tctgagtgtc tgccattcgg 2040
 tatttttaga ggtgcgtccaa agtcattagg aacaacctag ctcacgtact caattattca 2100
 aacaggactt attgggatc agcagtgaaat taagctttaaa aaataagata atgattgttt 2160
 65 ttatacccttc agtagagaaaa agtcttgca tataaagtaa tgttaaaaaa acatgtattt 2220
 aacacgacat tgtatgaaac acaataaaga ttctgaagct aaaaaaaaaaa

5 <210> 56
 <211> 1636
 <212> DNA
 <213> Human
 <400> 56

10 cttgaatgaa gctgacacca agaaccgcgg gaagagcttggcccaaagc agggaaaggga 60
 agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagccgg gcgccccac 120
 cagtttgatt ggaagtccag ctgtgaaacc tgagcgtcg cttctccccc agatggctcc 180
 tggtttgctt ggtctcaagg acactgcac tcaaaactga tccctggcc gttggaggag 240
 cagttcatcc ctaaagggtt tgaagccaaa agccgaagta gaaaaatga gacgaaagg 300
 cggggcagcc caaaagagaa gacgctgac tttggcaga ttgtctgggg gctggccttc 360

15 agcccggtgc cttccccacc cagcaggaag ctctggcac gccaccaccc ccaagtgc 420
 gatgtctctt gcctgggtct tgctacggga ctcaacgatg ggcagatcaa gatctgggag 480
 gtgcagacag ggctccctgt tttgaatctt tccggccacc aagatgtcg gagagatctg 540
 agcttcacac ccagtggcag tttgattttg gtctccgcgt cacggataa gactcttcgc 600

20 atctgggacc tgaataaaca cggtaaaacag attcaagtgt ttttttttgc ttttttttgc 660
 gtttactgtc gttccatctc cccagactgc agcatgtgt gtttttttgc ttttttttgc 720
 tcggtctttc tatggagcat gaggtccatc acgttaattt ggaagctaga gggccatcaa 780
 agcagtgttgc ttttttttgc 840
 gataccaaatg tgattatgtg ggaccctac accggcgaaa ggctgaggc actccaccac 900

25 acccagggttgc accccggccat ggttacatgtt gacgtccaca ttttttttgc 960
 tgcttctctc cagaaggctt gtaccttgc acgggtggcag atgacagact ctttttttgc 1020
 tggggccctgg aactgaaaac tccatttgc ttttttttgc 1080
 acattttttc cacatgggtgg agtattttgc acaggggacaa gagatggccaa ctttttttgc 1140
 tggacagctc ctagggcctt gtttttttgc aagtttttttgc 1200
 ttccttaacaa ctttttttgc 1260
 30 acatacagga ctttttttgc aacaccatctt ttttttttgc 1320
 ctttttttgc 1380
 ttttttttgc 1440
 ttttttttgc 1500
 35 aagacaattt gatacataat aaaaaattt gataatgtcc tggaaaaaaa aaaaatgtaga 1560
 aagatggtga agggtggat ggttggggat ctttttttgc 1620
 gaccctgtgc ttttttttgc

<210> 57
 <211> 460
 40 <212> DNA
 <213> Human
 <400> 57

45 ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcaacta ggcgcataatgt 60
 gcctccagggg ggctgcagat gtgtctgagg gtgagcctgg taaaagagaa gacaaaagaa 120
 tgaaatgagc taaagcagcc gcctgggtg ggaggcccgag cccatttgc tgcagcagg 180
 ggcaggagcc cagcaaggga gcctccatttcc ccaacttgc ttttttttgc 240
 50 atgcccgcac agccctccct cacactccat cctgtccac cctaatttgc caggtgggg 300
 aactgaggct gggaaagtac atagcaagtgc actggcagag ctgggactgg aacccaacca 360
 gcctcctaga ccacggttct tcccatcaat gaaatgtca agactccac caggtgggg 420
 ccgagctcga attcgtaatc atggtcatag ctgttttgc

55 <210> 58
 <211> 1049
 <212> DNA
 <213> Human
 <400> 58

60 atctgatcaa gaataacctgc cttggtcaact ctgcggatgt ttctgtccac ttttttgc 60
 tgaggaccaa gatattttt ttttttttgc ttttttttgc 120
 tgacgacatg ctggcataca ttttttttgc ttttttttgc 180
 cagcagcaact ttttttttgc ttttttttgc 240
 65 gtcagtgtct gtgcagggttgc ttttttttgc ttttttttgc 300
 ggttggggat ggttggggat ttttttttgc ttttttttgc 360

aaaatgtaaa cttcacccat ttcatcttct ccaaattccca agatgtgacc ggaaaagtag 420
cctctacagg acccaactgt gccgacacag agtggtttt cttgccactg ctttgcaca 480
ggactttgct ggagagttag gaaattccca ttacgatctc caaacacgt a gttccatac 540
5 aatcttctg actggcagcc ccggatataca aatccaccaa ccaaaggacc attactgaat 600
ggcttgaatt ctaaaagtga tggctcaatt tcataatctt tccccttat tatctgtaga 660
attctgctg atgatctgtt tttccattt gaggctgaac acagtatcgtaaaattgtatg 720
tttatatcg tggatgtct atccacagca catctgcctg gatctggag cccatgagca 780
aacacttcgg ggggctgggtt ggtgctgtt aagtgtgggt tgctccttgg tatgaaataa 840
10 ggcacgttgc acatgtctgt gtccacatcc agccgttagca ctgagcctgt gaaatcactt 900
aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
aaaaacccgt cagggccaaa gagcagtgc cctccagat gcttctgtg gagttctgca 1020
acttcaagaa agactctggc tttctcaa

<210> 59
15 <211> 747
<212> DNA
<213> Human

<400> 59
20 ttttcaaat cacatatggc ttctttgacc ccatcaaata actttattca cacaacgtc 60
ccttaattta caaaggctca gtcattcata cacatttaggg gatccacagt gttcaaggaa 120
cttaaatata atgtatcata ccaacccaaag taaaccaagt aaaaaaaata ttcatataaa 180
gttgttcaca cgtaggtcct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
25 atagatttat taacttagtat tggaaactaa cttctgtgcct ggctaaaac ctccctcact 300
ctcgtctgtc ccacacaaat gtttaagaag tcactgcaat gtactccccg gctctgtatg 360
aaagaagccc ctggcacaaa agattccagt gcccctgaag aggtccctt cctcctgtgg 420
gctctccatg aaaaccagcg ggacggcctc cctgctgata ccgtctataa ctttaggggg 480
30 ccctcggca ggcaacggca gtggactcat ctcgggtatg gctgttagatg ctaacactgg 540
ccaatcaat ggcacaccta ctggttaccc ttgaggggca tttctccaga cagaagcccc 600
ttgaaggcta ggttagggcag gatcagagat acacccgtgt ttgtctcgaa gggctccaca 660
gcccagtacg acatgttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
cgcgaattta gtagtaatag cggccgc